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Chapter 1    General introduction                                                                                                          
 
Part One: Virus  
• Hepatitis virus  
Hepatitis B virus (HBV), discovered in 1966, is a major public health 
problem which affects more than 350 million people worldwide.[1] The 
distribution of HBV infection varies worldwide. More than half of the population 
living in areas such as Southeast Asia, China, and Africa have been infected 
by HBV. Modes of disease transmission can be either through neonatal 
transmission (vertical) or transmission from one child to another (horizontal). 
As for the developed countries, which include North America, Western 
Europe, and Australia and are characterized by low levels of endemicity, most 
HBV infections result from horizontal transmission among adults, such as 
sexual activity, injection-drug use (IDU), or occupational exposure.[1, 2] The 
life cycle of HBV is characterized into four stages present in all infected 
patients. The first stage is characterized by immune tolerance. During the 
second stage an immunological response develops or increases in strength. 
When the host is able to eliminate HBV-infected cells or diminishes their 
number considerably, then active viral replication ends, which is followed by 
the third stage. Most HBV infected individuals eventually become negative for 
HBsAg and positive for anti-HBsAg, marking the fourth stage in the HBV life 
cycle.[1] For those getting rid of the infection, the short-term (six-month) 
infection is called acute hepatitis B. In other words, if HBV infection lasts 
longer than six months, it is considered a chronic HBV infection (CHB). 
Chronic hepatitis B is associated with some severe liver diseases, such as 
hepatic steatosis, inflammation, fibrosis, cirrhosis, and hepatocellular 
carcinoma (HCC).[3] Especially for the life-threatening conditions like cirrhosis 
and HCC, it is estimated that, of the patients with CHB, there are 20% 
developing cirrhosis,[4] and moreover, they are 100 times more likely to 
develop HCC than non-CHB.[5] With respect to the underlying mechanism of 
the development of chronic infection with HBV, HLA phenotype is one the 
factors influencing the response to infection with this virus.[6] In a clinical 
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setting, histological examination is considered an integral part when 
evaluating CHB patients, and the evaluation of the CHB associated liver 
damage is critically important for making decisions in antiviral therapy and 
need for further surveillance.[7] Thus liver biopsy remains the golden standard 
in assessing the severity of inflammation and fibrosis.[7, 8] However, the 
procedure is costly, sensitive to sampling errors, and a potential cause for 
complications.[9] Therefore, a reliable non-invasive diagnostic tool is urgently 
needed.  
Two strategies – vaccination and antiviral treatment – are traditionally 
implemented to manage hepatitis B infection. HBsAg remains the basis for the 
different HBV vaccines globally available. Antibody development to HBsAg, 
which is detectable in patients who have recovered from an acute hepatitis B 
infection and also those in people immunized with HBV vaccine, confers 
protective immunity. Being highly cost-effective, HBV vaccination has now 
been introduced into many nation-wide vaccine programs in a variety of 
countries. Based on the great success of this vaccination, it is estimated that 
universal childhood hepatitis B vaccination will eventually prevent more than 
80 percent of HBV-associated mortality globally.[11] The second important 
strategy is the implementation of antiviral therapy, the goal of which is to 
decrease the morbidity and mortality related to CHB.[8] One best predictor to 
assess the success of current therapy, HBsAg loss, however, is infrequently 
observed in current therapy.  
Mirroring the situation associated with HBV also the Hepatitis C virus 
(HCV), another important and prevalent hepatotropic virus, is also a critical 
public health problem affecting 130 million people worldwide.[12] Prevalence 
of HCV shows significant geographical variation in Europe. IDU appears to be 
the major risk factor for HCV infection in this continent.[13] HCV is related to 
development of HCC, and this appears to be mainly through fibrosis 
development.[6,14]  
 
• Human immunodeficiency virus (HIV) 
HIV affects 40 million people worldwide.[12] As estimated by the Chinese 
health authority,[15] there were 501,000 people living with human 
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immunodeficiency virus (HIV/AIDS) by the end of 2014 in China, accounting 
for 0.037% of the total population. Despite of a low national prevalence rate, 
the HIV infection is reaching epidemic rates in some areas of the Southwest 
China, in particular the Yunnan, Sichuan, and Guangxi provinces. Yunnan is 
the area most affected by HIV/AIDS in China. The epidemic has spread from 
high-risk groups including drug users, sex workers and unsafe blood 
recipients to the general population. Within a population of 44 million, officials 
estimate that this province has 80,000 HIV infected individuals.        
Antiretroviral drugs in applied in combination therapy consisting of three 
or more drugs hailing from more than one class of biological mechanism, 
often called “highly active antiretroviral therapy (HAART)”, are very effective in 
suppressing HIV, although this does not eradicate the virus. Since the first 
introduction of HAART in the mid-1990s, it has led to an unprecedented 
decline of mortality caused by HIV/AIDS both in the USA and Europe.[16,17]  
Because of the great success of HAART in treating HIV/AIDS in the 
developed countries, the World Health Organization (WHO) has promoted a 
public health approach to scale up the access of antiretroviral therapy in 
resource-limited setting since 2002.[18] As an emergency response to save 
and improve the lives of AIDS patients in China, the China National Free 
Antiretroviral Treatment Program (NFATP) was piloted in 2002 and scaled up 
in 2003 national wide.[19] Until 2014, a total of 295,358 patients in China have 
received HAART, and thus a large proportion of HIV patients have benefited 
from this program. 
Still, it is of importance to identify prognostic factors for survival among 
HIV-infected patients receiving HAART. Based on previous studies, the main 
risk factors for death include baseline low CD4 cell count, old age and 
advanced WHO stage. With respect to these earlier results, especially the 
prognostic value of CD4 cell counts seems unequivocal, even if being an 
imperfect measure of prognosis.[20-25] A recent study suggested that 
patients with low baseline CD4 cell counts only display increased mortality 
risk for up to 5 years after HAART.[26,27] This indicated the effect of CD4 cell 
count on the long-term survival is temporally speaking dynamic; however, this 
observation requires validation in other studies to substantiate this notion.                                
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• Coinfection  
As pointed out above, HBV and HCV are both important global health 
problems, and can cause severe liver disease. Many intravenous drug users 
have detectable antibodies to HBcAg and HCV in their circulation and 
injection needles are considered an important source of disease transmission 
and coinfection with hepatitis virus among HIV infected patients. Coinfection 
of HIV with hepatitis B virus (HBV) or hepatitis C virus (HCV) frequently 
occurs. Approximately 5 to 20% of the HIV-infected population is estimated to 
be co-infected with HBV and for HCV this figure is estimated be around 5 to 
15%. Of note, coinfection rates differ significantly according geographic 
regions for different types of hepatitis viruses.[28]  
However, it remains controversial to which extent coinfection with 
hepatitis virus impacts on the clinical outcome for patients with HIV infection 
receiving HAART. For instance, one study reported that HBV infection neither 
alters the clinical outcome of HIV infection nor could an effect be detected the 
other way around,[29]. In apparent disagreement, however, another study 
demonstrated that HBV is significantly related to high mortality in HIV 
patients.[30] Similarly, inconsistent data have been reported for HCV 
coinfection as well.[31,32] Therefore, further study is required to characterize 
the relationship between hepatitis virus coinfection and mortality in HIV 
infected patients.  
 
Part Two: Cancer 
• Global burden of HCC attributable to virus  
Hepatocellular Carcinoma (HCC) is the fifth most common malignancy and 
the second leading cause of cancer-related death worldwide.[33] Prognosis of 
patients with advanced stage HCC is poor, with median overall survival below 
20 months.[34]  Importantly, cancer in the liver can often develop as a 
consequence of an earlier infection and thus their relation is important subject 
for study. The attributable fraction (AF) is commonly used in epidemiological 
studies to quantify the burden of the relevant factor poses in causing a 
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particular disease. AF, in this study, means the proportion of new cancer 
incidences that would have been theoretically be avoided if exposure to a 
specific viral factor was modified or removed.[35] AFs estimates for all 
cancers worldwide and viral-associated cancers worldwide in 2012 are 
displayed in Figure 1.    
 
 
 
Figure 1  AFs for all cancers (left stacked bar) and viral-associated cancers worldwide in 2012 
(right stacked bar). In the formula, R indicates the relative risk associated with exposure. pc 
indicates the prevalence of cases. Data is calculated from the original data in a previous study 
(reference No.35),   
 
HBV and HCV are two important factors of HCC development. HBV and HCV 
caused 420,000 and 170,000 new cancers in 2012.[35] The incidence of HCC 
is much higher among HIV patients co-infected by hepatitis virus than in 
patients infected only by hepatitis virus. 
 
• Prognostic factors in HCC natural history of disease  
Racial disparity in survival among American population with HCC has been 
identified in several studies. In particular, poor survival of African Americans 
has been noted. Ethnicity-dependent natural history of disease has been 
documented demonstrated for HCC in the United States (U.S.) in several 
studies.[36-38] To improve the quality of health care for HCC patients, it is 
important to identify the factors affecting this ethnical disparity in overall 
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survival rates (OS), and to compare their impact. As a matter of fact, several 
factors associated with tumor presentation at time of diagnosis, type of 
surgical treatment, and socioeconomic status (SES), have previously been 
studied with regard to ethnic disparity in OS for HCC patients, but many 
questions remain and require urgent clarification.  
• Therapeutic treatment of HCC 
Surgical resection and liver transplantation are the only potentially curative 
treatment for a small proportion of early stage patients of HCC. Sorafenib was 
an only FDA approved systematic chemotherapy to treat patients with 
advanced HCC, which could only increase overall survival with 2-3 
months.[39] Therefore, new strategies to improve the prognosis of HCC 
patients are necessary.   
 
Scope and aims of this thesis 
Much of liver pathology is related to infection with HBV and HCV and it is important 
to define factors associated with clinical behavior of disease following infection with 
these viruses. Thus in this thesis I first focus on the natural history of chronic viral 
diseases associated with HBV or HCV infection, also in relation to HIV coinfection. 
Problem is that disease progression and its effects on liver physiology can be difficult 
to monitor and often reliable determination of liver health currently involves highly 
invasive liver biopsies. Evidently, serum based markers would bring disease 
monitoring forward and thus allow more precise analysis of disease course and thus 
also aids delineation of risk factors associated with alternative outcome. To address 
this void I first explore a potential clinically useful biomarker, cytokeratin-18. Its 
potential in monitoring chronic hepatitis is documented in Chapter 2. Concomitantly, 
however, I also tried to characterize  the general beneficial effects of antiretroviral 
therapy in patients with HIV infection. To this end a big cohort from Yunnan province 
in China was analyzed for identification of the factors associated with overall survival 
and the results, described in Chapter 3, show that especially CD4 counts are 
important, but only in the early course of disease. This highlights the care that should 
be taken when interpreting biological information in chronic disease and highlights 
the importance of defining novel markers specifically aimed at assessing disease 
course in chronic patients (as I attempted in chapter 2) but also in general show that 
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careful of epidemiological data is necessary and one should be careful not to over-
extrapolate results obtained, a theme that will also emerge from other parts of this 
thesis. Indeed. prevalence of coinfection with hepatitis virus and its impact on clinical 
outcome of patients with HIV infection were explored in chapter 4 and also show 
this: no negative impact of coinfection was found on the overall survival of these 
patients treated with HAART and thus the notion that more infection means more 
disease is simplistic. Due to the fact that chronic HBV/HCV infection is associated 
with developing HCC, I subsequently focus in this thesis is on the clinical outcome of 
patients with HCC. In particular, because of the existing racial disparity in overall 
survival for American patients with HCC, I aimed to identify the actual contributors to 
such disparity based on the Surveillance, Epidemiology, and End Results (SEER) 
database (Chapter 5). Again the result show a surprising correlation to the time 
domain: even many years after diagnosis racial disparity is maintained. The notion 
that racial disparity is driven access to health care thus appears an oversimplification 
and highlights the importance of studies exactly dissecting the contribution of 
different factors to disease course and the necessity of careful study of their 
relationship to continuous variables in the study cohort, especially the time domain. 
These lessons were taken into account in the last experimental chapter (Chapter 6) 
in which I study a potentially effective anti-HCC treatment, metformin, which was 
systematically analyzed via the meta-analysis method. The relationship between 
these findings and their place in the contemporary body of literature are presented in 
a general discussion on this thesis (Chapter 7). In conjunction I hope my studies will 
contribute to better clinical management of liver disease. 
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Abstract 
Caspase-cleaved cytokeratin 18 (CK18-Asp396) is a potential clinically useful 
biomarker in liver disease as it is released from hepatocytes during apoptosis. Here 
we investigate serum CK18-Asp396 levels in chronic hepatitis B (CHB).  Overall 163 
patients with CHB were included. Serum CK18-Asp396 were determined by elisa 
and results were related to steatosis grade, histological activity index (HAI), 
inflammation score, and METAVIR fibrosis grade in parallel obtained liver biopsies 
as well as to viral load, serum levels of liver enzymes and albumin. Receiver 
operating characteristic (ROC) analysis was used to evaluate the diagnostic 
performance of serum CK18-Asp396 levels for assessing disease activity. A higher 
level of serum CK-18 concentrations was found in patients with significant 
inflammation vs no significant inflammation (378.5 [IQR:173.2-629.6]  vs 137.3 [87.5-
197.7], P < 0.05) and in patients with significant fibrosis vs no significant fibrosis 
(177.8 [IQR:120.8-519.1]  vs 142.7 [IQR:88.8-214.4], P < 0.05). There was no 
differential CK-18 level by degree of steatosis. CK-18 was an independent predictor 
for significant inflammation with an 82% specificity and a 94% negative predictive 
value. We found the strongest correlation of CK-18 with ALT and AST(both r = 0.52; 
P < 0.001), less with Albumin (r = -0.24; P < 0.05) and viral load (log) (r = 0.19; P < 
0.05). CHB is accompanied by continuous high levels of hepatocyte apoptosis, 
suggesting that elimination of the infected compartment constitutes a defensive 
strategy against disease. Accordingly, CK-18 works as an independent predictor for 
significant inflammation with a high specificity. 
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Plain language summary   
 
In recent years it has become clear that serum levels of a fragment of cytokeratin 18 
(so-called caspase-cleaved cytokeratin 18) reflects the amount of programmed cell 
death in the liver. It remains, however, obscure whether programmed cell death is in 
general important during hepatitis B infection and specifically whether serum levels 
of caspase-cleaved cytokeratin 18 can be a marker for disease severity in hepatitis 
B. Here we show that liver inflammation of hepatitis B is characterized by high levels 
of called caspase-cleaved cytokeratin 18 and this novel marker for hepatitis B-
associated inflammation is potentially superior to currently used serum markers. 
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Introduction 
Chronic hepatitis B (CHB) infection is a major public health problem, which affects 
more than 350 million people worldwide[1]. It is well known that CHB is associated 
with hepatic steatosis, inflammation, and fibrosis[2-5]. Hence, histological 
examination is an integral part of evaluating CHB patients. Evaluation of the CHB 
associated liver damage is critically important for making decisions in antiviral 
therapy and need for surveillance[6]. Liver biopsy remains the golden standard in 
assessing the severity of inflammation and fibrosis [6, 7]. However, the procedure is 
costly, sensitive to sampling errors, and a potential cause for complications[8]. 
Therefore, a reliable non-invasive diagnostic tool is urgently needed. 
An increasing number of studies have emerged to explore potential non-
invasive tools. Given the importance of apoptosis in development of chronic liver 
disease in general[9-11], the importance of apoptosis in chronic hepatitis B remains 
unclear, and studies are hampered by the difficulty of distinguishing apoptosis in the 
hepatocyte compartment and the lymphocyte compartment. The former may 
represent efforts of the body to limit the size of the infected compartment and may 
thus be associated with antiviral responses in lieu of viral clearance and 
consequently with aggravated inflammation[12] and progression to HCC[13]. 
Apoptosis in the lymphocyte compartment is however associated with reduced 
inflammatory activity[14]. Hence studies looking specifically at hepatocyte apoptosis 
are urgently needed to characterize the role of programmed cell death in CHB and 
hepatocyte-specific apoptosis markers may also have substantial diagnostic value. 
In this context cytokeratin-18 (CK-18) is interesting. Expression of CK-18 is 
limited to certain endodermal derivatives, but is most prominently expressed in 
hepatocytes[15]. During hepatocyte apoptosis CK-18 is subject to specific cleavage 
by caspases, resulting in the release of neo-epitope (CK18-Asp396), which is not 
detectable in necrotic or vital cells[16]. Cytokeratin-18 (CK-18) is the best described 
hepatocyte-specific apoptosis marker[17], and many studies investigated the 
potential value of CK-18 as a non-invasive marker in predicting severity of steatosis, 
inflammation, and fibrosis. Previous studies have shown that increased levels of  
CK18-Asp396 are associated with CHB [18, 19] and relates to the severity of 
steatosis[20]. In addition, CK18-Asp396 can be a predictive marker for distinguishing 
between inactive carrier and HBeAg-negative CHB [21] and CK-18 correlate with the 
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presence of significant fibrosis in chronic hepatitis C (CHC)[22], non-alcoholic fatty 
liver disease (NAFLD)[23], as well as cirrhosis associated with CHB [24]. Thus CK-
18 appears useful to measure hepatocyte apoptosis in CHB and its measurement 
would allow making correlations between hepatocyte programmed cell death, 
inflammatory responses and viral load, allowing assessment as to the extent  to 
which hepatocyte apoptosis contributes to anti-viral defense.  
Here we measured CK18-Asp396 in a group of CHB patients in a well 
characterized Dutch cohort which includes patients across all grades of steatosis, 
inflammation and fibrosis. The results show that CK18-Asp396 is associated with 
hepatic inflammation and diagnostically useful for clinical determination of this 
condition. Furthermore the results support the notion that hepatocyte apoptosis may 
contribute to limiting the size of the virus-infected compartment.  
 
Results 
Patient characteristics 
The characteristics of the patients are described in Table 1. The mean age of the 
163 patients was 40 years old. In terms of inflammation, there were 22 patients with 
significant inflammation (grade ≥ 7), which accounted for 13% of total patients. As for 
fibrosis, there were 33 cases with significant fibrosis (advanced fibrosis or cirrhosis), 
accounting for 20% of patients. Finally the grade of steatosis was considered as 
normal in 2 patients (1%), mild  in 104 patients (64%), moderate in 44 patients (27%) 
and severe in 13 patients (8%).  
Elevated serum CK-18 levels in patients with significant inflammation and 
fibrosis 
Figure 1 displays the serum CK-18 levels across patients when differentiated to 
either steatosis grade, severity of inflammation or to fibrosis grade. When comparing 
steatosis grade the difference in CK-18  serum levels was not significant (P > 0.05). 
However, there were significant differences in CK-18 levels among different grades 
of inflammation and fibrosis. Patients with significant inflammation had a higher CK-
18 serum level than those with no significant inflammation (378.5 [IQR:173.2-629.6]  
vs 137.3 [87.5-197.7], P < 0.05). Similarly, patients that presented with significant 
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fibrosis had a higher CK-18 level than those with no significant fibrosis (177.8 
[IQR:120.8-519.1]  vs 142.7 [IQR:88.8-214.4], P < 0.05). Correlation of CK-18 serum 
levels was analyzed with several other clinical parameters recorded in this cohort 
(Table 2). In terms of biochemical parameters, the strongest correlation was with 
ALT and AST(both r=0.52; P < 0.001), followed by a negative correlation with 
Albumin (r = -0.24, P < 0.05) and a positive correlation with viral load (log) (r = 0.19, 
P < 0.05). No correlation with either age or BMI was found (P > 0.05). Among the 
histological parameters, CK-18 correlated best with the grade of inflammation (r = 
0.37; P < 0.001), followed by the grade of fibrosis (r = 0.18; P < 0.05). No correlation 
with steatosis was found(P > 0.05). Through multivariate analyses, adjusting for age, 
BMI, viral load (log), ALT level, ASL level and Albumin level, it was demonstrated 
that CK-18 serum levels can act as an independent predictor for the presence of 
significant inflammation (P < 0.05), but not for significant fibrosis (P > 0.05).  
 
Predictive value of CK-18 for significant inflammation  
We then assessed the potential value of CK-18 as a diagnostic tool by estimating 
AUROC, sensitivity and specificity. The AUROC of CK-18 for predicting significant 
inflammation was 0.81 (95%CI: 0.72-0.91) (Figure 2). Sensitivity, specificity, 
positive/negative predictive values, and positivity/negative likelihood ratios are 
summarized in Table 3. Of note, all these values were calculated according to the 
optimal cut-off points of CK-18 levels: 243.0 U/L. Although CK-18 had a low 
sensitivity of 68% and a very low positive predictive value of 37%, it showed a high 
specificity of 82% and a high negative predictive value up to 94%.  
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Figure 1 Boxplots of serum CK 18 levels in relation with steatosis, inflammation, and fibrosis in CHB 
patients. 
 Notes: (A) No difference across grades of steatosis (P > 0.05); (B) significant differences between 
significant and no significant inflammation ( P < 0.05); (C) significant differences between significant 
and no significant  fibrosis (P < 0.05).  
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Figure 2 Predictive value of CK 18 for significant inflammation. 
Notes: We assessed the potential value of CK 18 as a diagnostic tool by estimating AUC, sensitivity, 
and specificity. The AUC of CK18 for predicting significant inflammation was 0.81 (95%CI: 0.72-0.91).  
Abbreviations: AUC, area under the curve; ROC, receiver operating characteristic.  
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Discussion 
 
The contemporary of biomedical literature supports the notion that CK18-Asp396 
serum levels adequately reflect hepatocyte apoptosis[32]. In our study we exploited 
this notion to evaluate hepatocyte apoptosis in CHB. The study demonstrated that 
CHB is indeed associated with hepatocyte apoptosis, showing strong correlations 
with significant inflammation and fibrosis, but not with steatosis, and especially 
demonstrating a diagnostic value of CK-18 serum levels for identification of 
significant inflammation of the liver in CHB patients. The strong correlation with 
inflammatory responses suggests that hepatocyte apoptosis may serve as a strategy 
to limit the size of the HBV-infected compartment, a notion possibly supported by the 
observation that viral load shows only weak correlation with CK18-Asp396 serum 
levels, possibly reflecting functional effects of compartment size reduction. Future 
studies are necessary to substantiate this idea.  
A previously published study suggested a combination of routine tests as non-
invasive markers for liver inflammation and fibrosis [7]. In that report, a prediction 
model was suggested for identification of significant liver inflammation combining 
age, HBV DNA levels, AST, and albumin. However, in the current study, CK-18 
serum level was the single independent predictor based on our multivariate analysis. 
In terms of significant inflammation, CK-18 serum level was regarded as a good 
predictor with an 82% specificity and 68% sensitivity. The apparent superiority of 
CK18-Asp396 serum level determination over other non-invasive markers further 
highlights the intimate connection between CHB-associated inflammation and 
hepatocyte apoptosis.  
The diagnostic value of CK-18 serum levels for identification of significant 
inflammation in viral infection-associated chronic liver disease corresponds well with 
the findings of Bae et al. [21]. This study reports a high specificity of 89% for CK-18 
serum levels and a lower sensitivity of 45% for CHB patients, but also reported that 
the combination of CK-18 with AST yielded a much higher specificity up to 96% in 
their study, although simultaneously decreasing sensitivity to 38% [21]. As a liver 
enzyme, AST is more representative of hepatocyte death in general rather as 
indicating hepatocyte apoptosis per se.  In spite of a strong correlation between CK-
Predictive ability of CK 18 in severity of liver disease in chronic hepatitis B  
 
26 
18 and AST observed in our study, AST was not an independent predictor, 
suggesting that hepatocyte apoptosis and necrosis is a defining property in CHB. 
Considering significant fibrosis, CK-18 serum levels were previously reported 
as a useful predictor of this process in NAFLD patients [10, 23] and a correlation of 
CK-18 serum levels with fibrosis stage in CHB is supported by the observations of 
Sumer et al. [24]. Similar to our findings, these authors detect increased CK-18 
serum levels when significant fibrosis is present. Our data, however, indicate that 
CK-18 serum level cannot predict significant fibrosis independently, which also 
contrasts a recent study showing that CK-18 serum levels work independently as a 
predictor for the presence of significant fibrosis (F≥3)[10]. Generally speaking we feel 
that hepatocyte apoptosis is unlikely to have a causal relationship with the fibrosis 
process and in potential agreement the Rosso study presented a low AUROC value 
(0.61) for fibrosis with a sensitivity of 88% and a specificity of 38%. As a matter of 
fact, the beneficial role of apoptosis was ever reported in pancreatitis disease[33]. 
Indeed, transient elastography[34], measuring liver stiffness, was found to be a 
better predictor than CK-18 serum levels. To obtain a more accurate prediction for 
the presence of significant fibrosis, both markers, transient elastography and CK-18 
serum levels, were combined. Unfortunately, the combination performed not better 
than the transient elastogrpahy alone. In conclusion, we feel that CK-18 may have 
only  limited value for identification of significant fibrosis. 
In summary, our study has further demonstrated the predictive value of CK-18 
serum levels as a non-invasive marker for the presence of significant liver 
inflammation in CHB. Additionally, the potential combination with other non-invasive 
markers might improve the total performance, especially the sensitivity. With regard 
to the identification of significant fibrosis, we consider the limited diagnostic value of 
CK-18. Further study is required to identify more reliable and efficient non-invasive 
tool. Finally, our results support the notion that hepatocyte apoptosis has an 
important functionality in CHB pathogenesis. 
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Methods 
Patient selection 
This retrospective study includes 163 consecutive patients with CHB from 1985 to 
2012 at the Erasmus University Medical Center in Rotterdam, the Netherlands. 
Three indications were defined as an endpoint in this study: steatosis grade, 
inflammation, and fibrosis. Steatosis was classified into the following groups 
according to Brunt score[25]: <5%, normal; 5-33%, mild steatosis; 33-66%, moderate 
steatosis; >66%, severe steatosis. The inflammatory activity (grade) and the degree 
of hepatic fibrosis (stage) were assessed according to modified histological activity 
index (HAI) of Ishak system[26] and Metavir system (nil fibrosis F0, mild fibrosis F1, 
moderate fibrosis F2, advanced fibrosis F3, and cirrhosis F4), respectively[27]. For 
the purpose of this study, inflammation was divided into two groups: significant 
inflammation (grade ≥ 7) and non-significant inflammation (grade < 7). Similarly, 
fibrosis staging was divided in subgroups: significant fibrosis(stage ≥ 3) and non-
significant fibrosis (stage < 3)[7].  
This study was performed in accordance with the guidelines of the Declaration 
of Helsinki and the principles of Good Clinical Practice. Due to the retrospective 
nature of this study, the informed consent was not obtained from patients. Patients' 
identities were not revealed in our study. This study was approved by the ethical 
review board of Erasmus Medical Center (Rotterdam, The Netherlands)[28].  
 
Laboratory test  
Serum level of CK-18 was measured with the M30-Apoptosense enzyme-linked 
immunosorbent assay(ELISA) kit (VLVbio (PEVIVA), Nacka, Sweden) according to 
manufacturer’s instructions, which have been well established to accurately measure 
CK18-Asp396[29]. Each patient sample was measured in triplicate and the 
absorbance value was determined by microplate reader (FLUOstar Omega, BMG 
Labtech, De Meern, The Netherlands), according to routine procedures[30]. In short, 
the ELISA measures apoptosis in CK-18 positive cells, such as hepatocytes, with an 
antibody that specifically recognizes soluble caspase cleaved CK-18. 
Statistical analysis 
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Continuous variables were reported as mean (SD) or median(interquartile 
range[IQR]) according to data distribution, and categorical variables as percent. 
Quantitative variables were analyzed using t test for normal distribution data or 
Mann-Whitney U test for highly skewed data. The eventual diagnostic predictor value 
was calculated by receiver-operating curve (ROC). Youden index was used to 
determine the optimal cut-off value of CK-18. The probabilities of true positive 
(sensitivity) and true negative (specificity) were determined according to the 
calculated optimal cut-off value. The positive/negative likelihood ratio (LR+/LR-) were 
calculated by the following formula: LR+ = sensitivity / (1-specificity); LR- = (1-
sensitivity) / specificity. The area under the ROC curve (AUROC) was generated to 
assess the diagnostic performance of each independent predictor. ROC relevant 
analyses were done by using pROC package[31]. Correlation was calculated using 
Spearman’s rank correlation coefficient. All statistical analyses were performed in R 
software(version 3.2.0), and statistical significance was set at P < 0.05 (two-tailed).    
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Table 1 Clinical characteristics of  patients with chronic hepatitis B-virus infection (CHB)  
Characteristics 
All Patients            
(n=163) 
Significant 
Inflammation          
 (n= 22) 
No Significant 
Inflammation         
(n=141)                 
Significant  
Fibrosis  (n=33)               
No Significant  
Fibrosis                 
(n=130)        
Gender, n(%)  
     Male 136 (83) 18 (18) 118 (84) 28 (85) 108 (83) 
Female 27 (17) 4 (82) 23 (16) 5 (15) 22 (17) 
Age, years 
     Mean [SD] 40.0 [11.5] 45.5 (13.1) 39.1 [11.0] 47.2 [12.1] 38.1 [10.6] 
Median [IQR] 41.0 [31.0-48.0] 47.5 [35.3-55.8] 39.0 [31.0-46.0] 48.0 [39.0-56.0] 37.0 [30.3-45.8] 
Race, n(%)  
  
  
  Caucasian  84 (52) 12 (55) 72 (51) 18 (54) 66 (51) 
Asian 51 (31) 8 (36) 43 (30) 11 (33) 40 (31) 
African/Black  23 (14) 1 (5) 22 (16) 4 (12) 19 (15) 
Other Race 5 (3) 1 (5) 4 (3) 0 (0) 5 (4) 
BMI 
     Mean [SD] 27.2 [4.1] 27.5 [4.0] 27.2 [4.2] 27.1 [3.3] 27.3 [4.3] 
Median [IQR] 27.0 [24.8-29.8] 28.6 [25.6-30.1] 27.0 [24.8-29.8] 27.2 [24.8-29.2] 27.0 [24.8-29.8] 
HBeAg Status, n(%) 
     Positive 58 (36) 13 (59) 45 (32) 11 (33) 47 (36) 
Negative 105 (64) 9 (41) 96 (68) 22 (67) 83 (64) 
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ALT, xULN, U/L  
     Mean [SD] 2.3 (3.9) 3.2 [1.8] 2.2 [4.1] 2.4 [1.8] 2.3 [4.3] 
Median [IQR] 1.5 [1.1-2.2] 2.8 [1.9 -4.6] 1.4 [1.1-1.9] 1.8 [1.0-3.4] 1.5 [1.1-2.0] 
AST, xULN,U/L 
     Mean [SD] 1.4 [1.2] 2.1 [0.9] 1.2 [1.2] 1.8 [1.1] 1.3 [1.2] 
Median [IQR] 1.0 [0.8-1.4] 1.9 [1.5-2.6] 1.0 [0.8-1.2] 1.5 [1.0 -2.1] 1.0 [0.9-1.2] 
ALK 
     Mean [SD] 79.9 [64.5] 85.6 [33.8] 78.9 [68.6] 82.4 [28.5] 79.2 [71.2] 
Median [IQR] 72 [60.0-89.0] 72.0 [63.0-97.0] 71.0 [59.0-86.0] 75.0 [62.8-90.5 71.0 [59.0-84.0] 
Albumin, g/L 
     Mean [SD] 45.0 [3.5] 42.4 [3.1] 45.5 [3.4] 42.8 [4.0] 45.7 [3.1] 
Median [IQR] 45.0 [43.0-47.0] 42.5 [40.0-45.0] 46.0 [44.0-48.0] 44.0 [40.0-45.3] 46.0 [44.0-48.0] 
Viral Load (log) 
  
  
  Mean [SD] 5.0 [2.9] 7.2 [1.9] 4.8 [2.9] 5.8 [2.4] 4.9 [3.0] 
CK-18 Serum Level, 
U/L 
     Mean [SD] 206.6 [190.5] 404.8 [236.6] 175.7 [162.6] 321.3 [304.1] 177.5 [135.7] 
Median [IQR] 150.6 [95.8-242.9] 
378.5 [173.2-
620.6] 137.3 [87.5-197.7] 177.8 [120.8-519.1] 142.7 [88.8-214.4] 
Significant Inflammation, n(%)  
    Yes (Grade ≥ 7) 22 (13%)  NA NA NA NA 
No (Grade < 7) 141 (87%)  NA NA NA NA 
Significant Fibrosis,  
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n(%)  
Yes (F ≥ 3)  33 (20%) NA NA NA NA 
No (F < 3)  130 (80%)    NA NA NA NA 
ALT, alanine aminotransferase; AST, aspartate aminotransferase 
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Table 2 Correlation of Clinical Parameters with CK-18  
Parameters rho P Value 
Age 0.04 0.603 
BMI 0.11 0.183 
ALT 0.52 <.0001 
AST 0.52 <.0001 
Albumin -0.24 0.015 
Viral Load (log) 0.19 0.017 
Steatosis 0.07 0.368 
Inflammation 0.37 <.0001 
Fibrosis 0.18 0.020 
 
  
  
 
 
Table 3 Performance of serum CK-18 levels for the diagnosis of significant inflammation and 
significant fibrosis  
  
Cut-off value  
(U/L) 
Sensitivity   
(%) 
Specificity         
(%) PPVa NPVa LR+a LR-a 
Significant 
inflammation    243.0  68 82 37 94 3.9 0.4 
aPPV indicates positive predictive value; NPV indicates negative predictive value; LR+ indicates 
positive likelihood ratio; LR- indicates negative likelihood ratio.  
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Abstract 
We aim to evaluate the overall survival and associated risk factors for HIV-infected 
Chinese patients on antiretroviral therapy (ART). 2517 patients receiving ART 
between 2006 and 2016 were prospectively enrolled in Yunnan province. Kaplan-
Meier analyses and Cox proportional hazard regression analyses were performed. 
216/2517 patients died during a median 17.5 (interquartile range [IQR] 6.8-33.2) 
months of follow-up. 82/216 occurred within 6 months of starting ART. Adjusted 
hazard ratios were10.69 (95%CI 2.38-48.02, p = .002) for old age, 1.94 (95%CI 1.40-
2.69, p < .0001) for advanced WHO stage, and 0.42 ( 95%CI 0.27-0.63, p < .0001) 
for heterosexual transmission compared to injecting drug users. Surprisingly, 
adjusted hazard ratios comparing low CD4 counts group (<50 cells/µl) with high CD4 
counts group (≥500 cells/µl) within six months after starting ART was 20.17 (95%CI 
4.62-87.95, p <.0001) and it declined to 3.57 (95%CI 1.10-11.58, p=.034) afterwards. 
Age, WHO stage, transmission route are significantly independent risk factors for 
ART treated HIV patients. Importantly, baseline CD4 counts is strongly inversely 
associated with survival in the first six months; whereas it becomes a weak 
prognostic factor after six months of starting ART.  
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Introduction  
As estimated by the Chinese health authority 1, there were 501,000 people living with 
human immunodeficiency virus (HIV/AIDS) by the end of 2014 in China, accounting 
for 0.037% of the total population. Despite of a low national prevalence rate, the HIV 
epidemic is severe in some areas of the Southwest China, in particular the Yunnan, 
Sichuan, and Guangxi provinces. Yunnan is the area most affected by HIV/AIDS in 
China. The epidemic has spread from high-risk groups including drug users, sex 
workers and unsafe blood recipients to the general population. With a population of 
44 million, officials estimate that this province has 80,000 HIV infected individuals.                                     
    Antiretroviral drugs in combination of three or more drugs from more than 
one class, often called “highly active antiretroviral therapy (HAART)”, are very 
effective in suppressing HIV, although do not eradicate the virus. Since the first 
introducing of HAART in the mid-1990s, it has led to an unprecedented decline of 
mortality caused by HIV/AIDS both in the USA 2 and Europe 3. Because of the great 
success of HAART in treating HIV/AIDS in the developed countries, the World Health 
Organization (WHO) has promoted a public health approach to scale up the access 
of antiretroviral therapy in resource-limited setting since 2002 4,5. As an emergency 
response to save and improve the lives of AIDS patients in China, the China National 
Free Antiretroviral Treatment Program (NFATP) was piloted in 2002 and scaled up in 
2003 national wide 6,7. Until 2014, a total of 295,358 patients in China have received 
HAART 1, and thus a large proportion of HIV patients have benefited from this 
program. Based on China national HIV database as well as a few local studies, an 
increasing coverage of antiretroviral treatment has significantly decreased HIV/AIDS-
related mortality 8-12. 
    It is important to identify prognostic factors for survival among HIV-infected 
patients receiving ART. Based on previous studies, the main risk factors for death 
include baseline low CD4 cell count, old age and advanced WHO stage. Among 
them, CD4 cell count was suggested as the most important prognostic factor based 
on the estimated hazard ratio values 9-11,13-21. According to those results, the 
prognostic value of CD4 cell count seems to be well established. However, a recent 
study, examining European and North American patients, suggested that patients 
with low baseline CD4 cell count only carry the burden of increased risk of death up 
to 5 years after ART 16. This indicated the impersistence of the CD4 cell count on 
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the increased mortality, although no other study has reported similar observation. In 
order to better understand the treatment outcome of HIV patients, we have carried 
out a large prospective cohort study with long-term follow up in China, enrolling 
patients from Zhaotong, a prefecture-level city located in the northeast corner of 
Yunnan province. In this study, we aim to evaluate the overall survival and 
associated risk factors for the HIV-infected patients on ART in this cohort, with 
particular focusing on the prognostic value of CD4 cell count.  
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Results  
Baseline Characteristics  
A total of 2517 patients (adult) before starting ART were enrolled between July 2006 
and April 2016 in this study. The baseline characteristics of the study population at 
start of ART are summarized in Table 1. Patients had a median age of 39 
(interquartile range 31-50) years. The number of male patients accounted for 59.9% 
of all patients. A total of 76.2% patients were married. As for the HIV transmission 
routes, more than two-thirds (71.9%) were infected through heterosexual; whereas 
10.5% through injecting drug use (IDU). In terms of WHO clinical stage, 78.9% 
received ART at stage I/II and 20.9% at stage III/IV. When measuring CD4 cell count 
on continuous scale, CD4 cell count had an overall median 281 (IQR 177-388) per 
µl. By dividing CD4 cell count into subgroups, there are 5% of patients presenting 
low CD4 cell count (< 50 per µl), and 66.9% presenting high CD4 cell count (≥ 200 
per µl).    
Cumulative mortality in study population  
The crude cumulative mortality for study population is displayed in Figure 1. Their 
median follow-up time was 17.5 (IQR 6.8-33.2) months. The cumulative probabilities 
for mortality were 9%, 13%, 19%, and 26% at 2 years, 4 years, 6 years, and 8 years, 
respectively. 8.6% (216/2517) of patients died during the follow-up period. Within 
these patients, 38.0% (82/216) died in their first 6 months. Patients who died at their 
first six months of follow-up period had a median age of 42.0 (IQR 34.3-60.0), 70.7% 
were male, and 57.3% were in advanced WHO clinical stage of III/IV. The 
continuous CD4 cell count had a baseline median 140 (IQR 59-236) cells/µl. 25.6% 
(21/82) patients were in low CD4 cell count stratum (lower than 50 per µl); while 
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26.8% (22/82) in high CD4 cell count stratum (200/µl or greater) (supplementary 
Table S1).  
 
 
 
 
 
 
 
Figure 1 Cumulative morality from all-cause mortality for study population with 290 human 
immunodeficiency virus (HIV) infection receiving antiretroviral therapy (ART). 291 Corresponding 
numbers at risk at different time-points have been indicated below 292 the graph. 
 
Prognostic values of baseline factors 
The associations of baseline factors at start of ART with mortality, estimated from 
crude and adjusted Cox models with time-dependent coefficients for CD4 cell count 
are shown in Table 2. Age and CD4 cell count were significant prognostic factors for 
survival (p <.0001 by log-rank test) based on crude survival analysis as shown in 
Figure 2 and Supplementary Figure S1. Of note, patients with low CD4 cell count 
(<50 cells/µl) had drastically increased risk for mortality at early follow-up time. In 
multivariate model, advanced WHO clinical stage (HR 1.94, 95%CI 1.40-2.69, p < 
.0001) and old age (>75 years) (HR 10.69, 95%CI 2.38-48.02, p = .002) were 
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significantly associated with worse survival; heterosexual mode was associated with 
better survival (HR 0.42, 95%CI 0.27-0.63, p < .0001) than injecting drug users.  
Varying hazard ratios for baseline CD4 cell count were observed in analysis for 
different time intervals since the start of ART. For instance, the adjusted HRs 
comparing low CD4 cell count group (<50 cells/µl) with high CD4 cell count group (≥ 
500 cells/µl) during the first six months was 20.17 (95%CI 4.62-87.95, p <.0001), but 
it became 3.57 (95%CI 1.10-11.58, p=.034) after the first six months. By comparing 
those with CD4 cell count (50-199 cells/µl) and high CD4 cell count (≥500 cells/µl), 
significant HRs were found in the two intervals: 5.06 (95%CI 1.20-21.32, p = .027) 
≤0.5 year and 2.89 (95%CI 1.02-8.04, p = .045) > 0.5 year (Table 2). With respect to 
the model accuracy, concordance with 0.791 suggested good predictive 
performance of the Cox model.  
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Figure 2 Cumulative morality from all-cause mortality for study population infected 294 by human 
immunodeficiency virus (HIV) receiving antiretroviral therapy (ART) 295 according to CD4 cell count 
(p <.0001). Corresponding numbers at risk at different 296 time-points split by CD4 cell count have 
been indicated below the graph.
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Table 1 Baseline characteristics of the patients according to whether lost to follow up or not 
 Characteristics Overall                (n=2517) 
LTFU                     
(n=199) 
Non-LTFU               
(n=2318) p-value
d                        
Gender, no. (%)       .512a 
Male 1507/2517 (60) 124/199 (62)  1383/2318 (60) 
 Female 1010/2517 (40)  75/199 (38) 935/2318 (40) 
 Marital status, no. (%)       .004a 
Unmarried 296/2501 (12) 39/197 (20) 257/2304 (11) 
 Married 1919/2501 (76) 137/197 (70) 1782/2304 (77) 
 Divorced  156/2501 (6) 10/197 (5) 146/2304 (6) 
 Widowed 130/2501 (5) 11/197 (6) 119/2304 (5) 
 Age at ART initiation, year       .137b 
Mean (SD) 42 (14) 40 (15) 42 (14) 
 Median (IQR) 39 (31-50) 36 (29-49) 39 (31-50) 
 WHO HIV Clinical Stage, no. (%)       .004a 
Stage I/II 1986/2511 (79) 158/197 (80) 1828/2314 (80) 
 Stage III/IV 525/2511 (21) 39/197 (20) 486/2314 (21) 
 CD4, cells/µl       .010a 
Median (IQR) 281(177-388) 330 (220-455) 278 (173-383) 
 <50 126/2402 (5) 5/179 (3) 121/2223 (1) 
 
Prognostic ability CD4 in patients with HIV infection 
 
50-199 593/2402 (24) 31/179 (17) 562/2223 (25) 
 200-349 895/2402 (37) 67/179 (37) 828/2223 (37) 
350-499                          478/2402 (20) 44/179 (25) 434/2223(20)  
≥500 310/2402 (13) 32/179 (18) 278/2223 (13) 
 Transmission category, no. (%)        
Injecting drug users (IDU) 263/2517 (11) 42/199 (21) 221/2318 (10) <.0001a 
Homosexual 54/2517 (2) 3/199 (2) 51/2318 (2) 
 Heterosexual 1809/2517 (72) 136/199 (68) 1673/2318 (72) 
 Others/unknownc 391/2517 (16) 18/199 (9) 373/2318 (16)  
Abbreviations: LTFU=lost to follow up; Non-LTFU=not lost to follow up; ART indicates antiretroviral treatment; SD=standard 
deviation; IQR=interquartile range.                                                                                                                                                  
aIndicates Pearson's Chi-squared test;                                                                                                                                       
bIndicates Welch Two Sample t-test;                                                                                                                                          
cInclude blood transfusion, mother-to-Child, and others;                                                                                                                                           
dBaseline characteristics were compared between patients of LTFU and patients without LTFU. 
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Table 2 Cox proportional hazard regression analyses analyzing all-cause mortality after starting ART  
Baseline characteristics 
Univariate analysis   Multivariate analysis 
Hazard ratio (95% CI) p value   Hazard ratio (95% CI) p value 
Gender            
Female 1 (Reference) 
 
1 (Reference) 
Male 1.74 (1.30-2.34) <.001 
 
1.26 (0.90-1.75)  .167 
Marital status          
Married 1 (Reference) 
 
1 (Reference) 
Unmarried 1.14 (0.78-1.68) .506 
 
 -  - 
Divorced 1.11 (0.64-1.92) .706 
 
 -  - 
Widowed 1.81 (1.05-3.14) .033 
 
 -  - 
Age at ART initiation, yeara          
(0,20]  1 (Reference) 
 
1 (Reference) 
(20,25] 1.07 (0.23-4.97) .929 
 
0.96 (0.20-4.47) .961 
(25,30] 1.47 (0.35-6.21) .604 
 
0.83 (0.20-3.63) .818 
(30,35] 1.99 (0.48-8.28) .344 
 
0.88 (0.21-3.79) .872 
(35,40] 2.10 (0.50-8.78) .308 
 
1.05 (0.25-4.47) .948 
(40,45] 2.26 (0.53-9.59) .271 
 
1.18 (0.27-5.09) .828 
(45,50] 1.81 (0.41-8.11) .435 
 
0.77 (0.16-3.60) .739 
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(50,55] 2.23 (0.49-10.17) .302 
 
1.45 (0.31-6.66) .636 
(55,60] 4.40 (1.02-18.91) .046 
 
2.92 (0.67-12.66) .153 
(60,65] 3.71 (0.82-16.57) .087 
 
1.84 (0.40-8.51) .436 
(65,70] 5.42 (1.20-24.49) .028 
 
2.96 (0.64-13.70) .165 
(70,75] 6.73 (1.49-30.40) .013 
 
2.45 (0.51-11.74) .264 
(75,90] 16.25 (3.73-70.85) .000 
 
10.69 (2.38-48.02) .002 
WHO HIV Clinical Stage          
Stage I/II 1 (Reference) 
 
1 (Reference) 
Stage III/IV 3.15 (2.40-4.13) <.0001 
 
1.92 (1.38-2.66) <.0001 
Transmission           
Injecting drug users (IDU) 1 (Reference) 
 
1 (Reference) 
Homosexual 0.34 (0.08-1.41) .137 
 
0.38 (0.09-1.59) .184 
Heterosexual 0.60 (0.43-0.84) .004 
 
0.42 (0.28-0.64) <.0001 
Others/unknownb 1.06 (0.71-1.59) .771 
 
0.62 (0.38-1.02) .060 
Baseline CD4, cells/µl          
  ≤0.5 years 
    
 
 ≥500 1 (Reference) 
 
1 (Reference) 
350-499 1.61 (0.31-8.30) .569 1.40 (0.27-7.25) .685 
200-349 2.53 (0.58-11.07) .217  2.14 (0.49-9.39) .312 
50-199 8.41 (2.01-35.07) .003 
 
5.06 (1.20-21.32)  .027 
Chapter 3 
 
 
47 
<50  28.51 (6.68-121.60) <.0001 
 
20.17 (4.62-87.95)  <.0001 
 >0.5 years 
 
  
  
 
 ≥500 1 (Reference) 
 
1 (Reference) 
350-499 1.89 (0.62-5.79) .267 1.73 (0.56-5.32) .338 
200-349 1.91 (0.70-5.35) .220  1.71 (0.61-4.81) .310 
50-199 3.93 (1.41-10.94) .009 
 
2.89 (1.02-8.04)  .045 
<50  4.94 (1.57-15.57) .006  3.57 (1.10-11.58)  .034  
Abbreviations: 95% CI =95% confidence interval; ART = antiretroviral therapy. 
aThe patient number in each age subgroup were the following:  
 (0,20] 50; (20,25] 185; (25,30] 369; (30,35] 383; (35,40] 389; (40,45] 295; (45,50] 226; (50,55] 158; (55,60] 147; (60,65] 122;  
(65,70] 80; (70,75] 67; and (75,90] 45.  
bIncludes blood transfusion, mother-to-Child, and others/unknown.   
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Discussion 
This is a large prospective study pioneering the assessment of patient survival 
and associated risk factors in Chinese population with HIV infection receiving ART. 
We described the treatment outcome and identified baseline age, WHO clinical stage 
as independent predictors for patients survival for all time. The low CD4 cell count at 
baseline had a strong inverse association with survival at first six months of starting 
ART.  
    The survival benefit from ART have been demonstrated intensively among 
the HIV infected patients2,3. A high tolerance of ART regimen and fewer regimen 
switches were found among our patients (Supplementary figure S2). Of the 
patients who died during the follow-up, more than two thirds occurred within the first 
six months since ART initiation, similar to previous studies11,14,22. The patient 
characteristics between those dead at first six months and the entire study 
population were clearly described in this study. The former group had a higher 
percentage of patients with old age, advanced WHO clinical stage (stage III/IV) and 
low CD4 cell count compared with the entire study population. Thus, poor baseline 
patient characteristics seem to contribute largely to the worse survival, supporting 
the importance of early diagnosis and treatment11,14,15,23-25. Overall, we feel that the 
first six months of ART is critical for improving survival outcome in HIV-infected 
patients.   
    The varying coefficients for CD4 cell count was demonstrated among our 
patients. Many previous studies only reported CD4 cell count as a strong prognostic 
factor for all time of their study period, but the potential varying effects of CD4 cell 
count on survival were hardly discussed in their studies9,11,21,26,27. A potential reason 
could be the lack of testing the proportional hazard assumption for Cox model, or 
such assumption was met in those studies. Another potential explanation could be 
the relatively short follow-up time in many previous studies. Taking this into 
consideration, a recent retrospective study with long-term follow-up (more than ten 
years) from the Antiretroviral Therapy Cohort Collaboration (ART-CC) have 
suggested that the baseline CD4 cell count is less prognostic after five years since 
starting ART16. In other words, the patients with low baseline CD4 cell count, who 
survived the first five years since ART, may expect similar mortality to that of patients 
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with high baseline CD4 cell count. In our prospective cohort study, a strong inverse 
association between baseline CD4 cell count and risk for mortality was also 
observed, but only for the first half year after starting ART. We observed a 10-fold 
increased mortality for low CD4 cell count, which was much higher than the 2.8-fold 
increase in the ART-CC study16. Of note, there are several differences between 
these two studies, in particular European Americans vs Chinese population. Another 
important difference to be noticed is the anti-HIV drugs used in those studies. The 
patients engaged in the ART-CC study received ART between 1996 and 2001; 
however, our patients have been treated since 2006 with the newer anti-HIV drugs. 
Given the fact that new drugs introduced since 2002 provide a better immunological 
response28,29, our data might reflect more the treatment effect on HIV infected 
patients nowadays. These factors may contribute to the discrepancies observed 
between our study and the previous ones. Besides, the CD4 cell count at six months 
after starting ART was also examined in our study for assessing its potential 
association with survival after six months of starting ART. In contrast to values at 
baseline, the six-month CD4 cell count was strongly associated with the worse 
survival for the period after six months of ART initiation. Consistently, the prognostic 
value of six-month CD4 cell count has been demonstrated previously30. To be 
noticed, due to the missing values of six-month CD4 cell count among the patients 
who had survived for six months (displayed in Supplementary Figure S3), these data 
were not shown in this study.  
    A potential limitation of this study is the lacking of baseline viral load. 
Although the primary aim of ART is to inhibit the viral replication and reduce viral 
load, the resulted increase of CD4 cell count is the main goal as it serves as the 
most important indicator of immune function in HIV-infected patients. Despite this, 
WHO clinical stage and particularly CD4 cell counts were analyzed. Therefore, the 
potential bias from not analyzing viral load have been largely circumvented by 
including the analysis of WHO clinical stage and particularly CD4 cell counts. 
Besides, the present study only analyzed the data which were collected at start of 
ART initiation. Although baseline CD4 cell count has been proven to be an important 
predictor for the long-term outcome of ART and patient survival19,31,32, the dynamics 
of CD4 cell count across follow-up period could also be very important, deserving 
further investigation. 
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    In conclusion, this is a large prospective study with long-term follow-up 
investigating the treatment outcome and prognostic factors for the HIV-infected 
patients receiving ART. Baseline characteristics including gender, age and WHO 
clinical stage are significantly associated with all-cause mortality. Importantly, we 
reported the time-dependent coefficients for CD4 cell count over different time 
intervals among Chinese population. The strong inverse association between CD4 
cell count and risk for mortality has been demonstrated for the first half year after 
starting ART. However, CD4 cell count at six month has a strong inverse association 
with survival after six months of starting ART. 
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Methods 
Study population 
A prospective cohort study was conducted by enrolling HIV patients at start of 
ART between 2006 July to 2016 April in Zhaotong, Yunnan province, China. Patients 
were enrolled from different areas of Zhaotong (a prefecture-level city), including 
Zhaoyang District, Ludian County, Qiaojia County, Yanjin County, Daguan County, 
Yongshan County, Suijiang County, Zhenxiong County, Yiliang County, Weixin 
County and Shuifu County. All patients were treated based on the criteria of the 
“National AIDS Free Antiviral Treatment Manual”, HIV drug resistance, individual 
health, and other factors. We collected data on demographics (age, sex, marital 
status, transmission category), histological parameter (WHO clinical stage), and 
laboratory maker (CD4 cell count) at baseline when patients initiated ART. 
The institutional ethical committee of the First Affiliated Hospital of Kunming 
Medical University has approved this study. Informed consent was obtained from all 
participants in this study. No personally identifiable information was seen and used in 
our data analysis. All the methods of this study were performed in accordance with 
the guideline and regulation of the institutional ethical committee of the First Affiliated 
Hospital of Kunming Medical University. 
Statistical Analysis 
All patients were followed up from the date since starting ART until the date of 
death, loss to follow-up, or the end of follow-up. Patients who were lost to follow-up 
or the event did not occur within the study duration were considered as censored 
cases. For the patients with treatment changes or interruptions, we analyzed the 
data as their intent to continue treatment, same as the other patients. 
    In descriptive statistics, continuous variables were reported as mean with 
standardized deviation (SD) and median with interquartile range (IQR). Categorical 
variables were reported as number with percentage. A crude survival analysis 
(Kaplan-Meier curve) was utilized to analyze the patients’ survival on ART during 10-
year follow up. An adjusted survival analysis, Cox proportional hazard regression 
analysis, was used to evaluate the factors related to survival outcome. Variables with 
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a p-value below 0.20 on univariate analysis were included in multivariate analysis33-
35. All statistical analyses were performed in R (version 3.3.1)36. Particularly, 
“survival” package37 was used for survival analyses. The loss to follow up and not 
loss to follow up against survival time were plotted to depict the their patterns 
(Supplementary Figure S4). The assumption of proportional hazards was tested 
both statistically (Supplementary Table S2) and graphically (Supplementary 
Figure S5) using function cox.zph. Besides, Concordance was calculated to assess 
the Cox model accuracy. One of the strengths of Cox model is its ability to 
encompass the time-varying coefficients. A step function was used to analyze the 
time-dependent effect of baseline CD4 cell count over different time intervals after 
breaking the data set into time dependent parts using survSplit function38. P < .05 
(two-tailed sides) was considered as significant. The R code for performing Cox 
proportional regression analyses in this study were shown in supplementary Figure 
S6. 
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Supplementary data 
 
 
Table S1 Baseline Characteristics of the Patients who Died at First  
6 Months of Follow-Up Period 
Characteristics Descriptive statistics 
  Total    
  no. 82 
  Gender, no. (%)   
  Male 58 (70.7) 
  Female 24 (29.3) 
  Marital status, no. (%)   
  Unmarried 11 (13.4) 
  Married 61 (74.4) 
  Divorced  3 (3.7) 
  Widowed 7 (8.5) 
  Age at ART initiation, year   
  Mean (SD) 47.6 (15.8) 
  Median (IQR) 42.0 (34.3-60.0) 
  WHO HIV Clinical Stage, no. (%)   
  Stage I/II 35 (42.7) 
  Stage III/IV 47 (57.3) 
  CD4, cells/µl   
  Mean (SD) 152.7 (128.9) 
  Median (IQR) 129.0 (44.5-215.0) 
  <50 21 (25.6) 
  50-199 32 (39.0) 
  ≥200 22 (26.8) 
  Transmission category, no. (%)   
  Injecting drug users (IDU) 12 (14.6) 
  Homosexual 0 (0) 
  Heterosexual 53 (64.6) 
  Others/unknown 17 (20.7) 
  ART indicates antiretroviral treatment   
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Table S2 Testing the Proportional Hazards Assumption of a Cox Regression Model Fita 
  rho chisq p 
Gender  
   Female    -    - (Reference) 
Male -0.014 0.040 .841 
Marital status 
   Married    -    - (Reference) 
Unmarried -0.071 1.073 .300 
Divorced 0.107 2.25 .134 
Widowed 0.066 0.991 .320 
Age at ART initiation, year 
   WHO HIV Clinical Stage 
   Stage I/II    -    - (Reference) 
Stage III/IV -0.081 1.536 .215 
CD4, cells/µl 
   ≥200    -    - (Reference) 
50-199 -0.104 2.425 .119 
<50 -0.150 5.029 .025 
Transmission category 
   Blood transfusion    -    - (Reference) 
Injecting drug users (IDU) -0.031 0.192 .661 
Homosexual 0.003 0.002 .957 
Heterosexual -0.039 0.296 .586 
Mother-to-Child -0.013 0.036 .850 
Others/unknown -0.022 0.093 .760 
GLOBALb NA 19.958 .096 
aCompuated by cox.zph() function in package of "survival" from R 
bIndicates the global test  
   rho = Spearman's rank correlation coefficient 
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Figure S1 Cumulative morality from all-cause mortality for study population infected by human 
immunodeficiency virus (HIV) receiving antiretroviral therapy (ART) according to age (p <.0001). 
Corresponding numbers at risk at different time-points split by age categories have been indicated 
below the graph. 
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Figure S2 The Pie Chart showing the percentage of patients who switched drugs during Antiretroviral 
Therapy. 
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Figure S3 Plots presenting the values of baseline CD4 counts and 6-month CD4 counts for the 
patients who had survived 6 months after antiretroviral therapy. (A): histograms for continuous data of 
CD4 counts; (B): stacked bar chart for categorical data of CD4 counts: <50, 50-199, and  ≥200 (unit: 
cells/µl).  
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Figure S4 Plot of loss to follow up or not loss to follow up against survival time.  LFU = loss to follow 
up; NLFU = not loss to follow up.  
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Figure S5 Plot of scaled Schoenfeld residuals against transformed time for covariate CD4 count in 
Cox model fit. The upper solid line is a smoothing spline fit to the plot, with the broken lines 
representing a ± 2-standard-error band around the fit; and the bottom solid line is a horizontal line.  
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# Import data........................................................................................................................... 
data1 <- read.csv ('HIV_data.csv') 
# Split dataset into two time intervals: <=0.5 year; >0.5 year................................................ 
data2<-survival::survSplit(Surv(time,event)~.,data1,cut=c(0.5), 
                 episode = "tgroup", 
                 id="id") 
# Cox model.......................................................................................................................... 
# 1.Univariate analysis  
## CD4 for two time intervals  
summmry(coxph(Surv(tstart,time,event)~CD4:strata(tgroup),data=data2) 
## Other factors  
variables<-c('sex','marriage','transmission','WHO_stage','age') 
lapply (variables, function(x)summary(coxph(Surv(time,event)~data2[,x],data=data2))) 
# 2.Multivariate analysis 
summary(coxph(Surv(tstart,Time_m,Event)~CD4:strata(tgroup)+sex+WHO_stage+age, data=base2)) 
 
Figure S6 R code for performing Cox proportional regression analyses 
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Abstract  
This study aimed to evaluate the prevalence and impact of coinfection with hepatitis 
virus on the overall survival among HIV patients treated with antiretroviral therapy 
(ART). A total 2517 patients receiving ART between 2006 and 2016 were enrolled in 
Yunnan, China. The prevalence and characteristics of hepatitis virus coinfection was 
determined for four groups: HIV only, HBV-HIV, HCV-HIV, and triple infection. The 
independent effects of coinfection on long-term overall survival were evaluated by 
both conventional and extended Cox proportional hazard models. Finally, potential 
correlation of coinfection with longitudinal changes of CD4 cell count was examined. 
1868 patients of the entire population have available data on coinfection with 
hepatitis virus. HIV mono-infection accounts for 82% (1537/1868). HBV or HCV 
coinfection are 8% (149/1868) and 8% (157/1868), respectively. There are 1% 
(25/1868) of patients having triple infection. We found that hepatitis virus coinfection 
has no significant negative effect on long-term overall survival: HBV-HIV (HR 1.32, 
95%CI 0.73-2.40, p=.359), HCV-HIV (HR, 0.71, 95%CI 0.32-1.57, p =.399), and 
triple infection (HR, 0.37, 95%CI 0.05-2.84, p=.342). Interestingly, within 24-month of 
ART, a remarkable increase of median CD4 cell count was observed among patients 
with HIV mono-infection, from a median of 294 (IQR: 180-412) cells/µl at baseline to 
401 (IQR:297-556) cells/µl at 24 months. We have determined the rates of hepatitis 
virus coinfection in a large HIV cohort from Yunan province of China. In our cohort, 
no negative impact of coinfection was found on the overall survival of these patients 
treated with ART. Interestingly, patients with HIV mono-infection have a better 
recovery of CD4 cell count.  
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Introduction 
By the end of 2014, there were approximately 501,000 people living with human 
immunodeficiency virus (HIV/AIDS) in China [1], representing 0.037% of the total 
population. Despite the relatively low prevalence rate national-wide, high prevalence 
of HIV infection is found mainly in Southwest China, among which Yunnan is the 
most affected area, with up to 80,000 infected individuals. 
Coinfection of HIV with hepatitis B virus (HBV) or hepatitis C virus (HCV) 
frequently occurs. In respect to the burden of chronic viral infections worldwide, HBV 
is estimated to accounting for 370 million, HCV for 130 million, and HIV for 40 million 
[2]. 5~20% of HIV-infected population are estimated to be co-infected with HBV and 
5-15% with HCV [3]. Of note, the burden of coinfection differs significantly by 
geographic regions for different types of hepatitis viruses, among different 
countries[3], and across different provinces in China [4-8]. Although previous studies 
have investigated the coinfection of HIV with hepatitis virus in China [5], those 
estimates were mainly based on relatively small population of particular provinces. 
The impact of coinfection on the mortality among HIV-infected patients 
receiving antiretroviral therapy (ART) has been highlighted [9]. Giving the significant 
improvement of patient survival by initiating ART [1, 10, 11], several important 
prognostic factors have been identified, including CD4 cell count, baseline age on 
ART and advanced stage [12-14]. However, it remains controversial regarding the 
association of coinfection and patient morality. A US cohort reported that HCV 
coinfection did not substantially impact the survival outcome [15], while a Chinese 
study indicated significant roles of both HCV coinfection and triple infection (HBV-
HCV-HIV) [7]. 
This study aimed to evaluate the prevalence, patient/disease characteristics, 
and the impact of coinfection on mortality of HIV patients in a large cohort from 
Yunnan province in China.  
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Results 
Patient characteristics by HIV and hepatitis virus infection  
There were 2517 patients on ART enrolled between 2006 to 2016 in Zhaotong, 
Yunnan province of China. Hepatitis coinfection data were available for a total of 
1868 patients. Characteristics for all patients according to hepatitis virus status are 
summarized in Table 1. 149 patients had HBV co-infection, 157 patients had HCV 
co-infection, 25 patients had triple infection, and 1537 had HIV infection only. A 
median age for entire population was 39 with interquartile range (IQR) between 31 
and 50. Male patients accounted for 60%. 79% of patients presented early stage of 
HIV infection (WHO Clinical Stage I/II). The median of CD4 cell count was 281 (IQR: 
177-388) cells/µl for the entire population.  
Prognostic value of hepatitis virus infection for HIV-infected patients 
Figure 1 displays the crude survival analysis by Kaplan-Meier curve by coinfection 
type for the overall population who had followed up to nearly ten years. As shown in 
the figure, there was no significant difference of survival probability among different 
coinfection groups (log-rank p = .53). 
The potential association of baseline factors on ART initiation with overall 
survival was evaluated as well in Cox models. Results from a conventional Cox 
model and an extended Cox model with time-by-covariate interaction term were 
summarized in Table 2. With conventional Cox model, assuming all covariates meet 
proportional hazard assumption, it turned out that sexual transmission (HR 0.33, 
95%CI 0.17-0.65, p < .01), baseline age on ART (HR 1.04, 95%CI 1.02-1.05, p 
<.0001), advanced WHO Stage (stage III/IV) (HR 2.13, 95%CI 1.44-3.17, p <.001), 
CD4 cell count (HR 1.00, 95%CI 1.00-1.00, p <.0001), AST (HR 1.01, 95%CI 1.01-
1.02, p <.0001), and ALT (HR 0.99, 95%CI 0.98-1.00, p =.049) are significant factors 
associated with overall survival. In contrast, hepatitis virus coinfection has no 
significant role for long-term overall survival, HBV-HIV (HR 1.32, 95%CI 0.73-2.40, 
p=.359), HCV-HIV(HR, 0.71, 95%CI 0.32-1.57, p =.399), and triple infection(HR, 
0.37, 95%CI 0.05-2.84, p=.342). Furthermore, testing proportional hazards 
assumption (Supplementary Table S1) revealed time-dependent coefficient for 
covariate of CD4 cell count. Thus, an extended Cox model was carried out to include 
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time-by-covariate interaction term. A significant interaction term between CD4 cell 
count and follow up time (log) was observed in this model. As shown in Table 2, 
statistical estimates for covariates were similar between conventional Cox model and 
extended Cox model.  
 
 
 
 
Figure 1 Cumulative probability of overall survival by hepatitis virus infection status: HIV only, HBV-
HIV co-infection, HCV-HIV co-infection, and triple infection. 
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Impact of coinfection on response to antiretroviral therapy 
Next, the potential role of coinfection of hepatitis virus on the longitudinal changes of 
CD4 cell count was evaluated. According to Supplementary Figure S5, majority of 
patients remained in the cohort for analysis until the first 24 months after ART 
initiation. As shown in Figure 2, baseline median CD4 cell counts were 294 (IQR: 
180-412) cells/µl, 276 (IQR: 165-412) cells/µl, 295 (IQR: 186-379) cells/µl, and 303 
(IQR: 239-368) cells/µl for groups of HIV only, HBV-HIV coinfection, HCV-HIV 
coinfection, and triple infection, respectively. For patients with HIV infection only, 
CD4 cell count kept increasing during 24-month treatment period, with median of 401 
(IQR:297-556) cells/µl. With coinfection of HBV or HCV, increased median CD4 cell 
count was observed in HBV-HIV(316; IQR: 186-390), and HCV-HIV (322; IQR: 184-
442) at 12 months, but it started decreasing afterwards. As for triple infection, a clear 
decrease of CD4 cell count (292 cells/µl; IQR: 260-336) was found since ART 
initiation till the 12 months. Although a significant increase of CD4 cell count was 
observed at 24 months, the data should be taken into caution due to small 
population remained by that time (only 4 patients). 
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Figure 2 The distribution of CD4 cell count at different time points of follow up for different patient 
groups. The midpoints of the vertical bars represent the medians, and the error bars represent the 
interquartile range of CD4 cell count. The x axe shows the time points of follow up, and y axe shows 
the CD4 cell count (cells/μl). 
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Table 1 Patient characteristics by HIV mono-infection, HIV-HBV or HCV co-infection status   
Characteristics Overall                              N = 2517 
HIV monoinfection                     
no. (%)  
HBV 
coinfection            
no. (%)  
HCV coinfection  
no. (%)  
Triple infection                     
no. (%)  
1868/2517 (74)  
Total 
 
1537/1868 (82) 149/1868 (8) 157/1868 (8) 25/1868 (1) 
Gender, no. (%)           
Male 1507 (60) 872/1537 (57) 108/149 (73) 114/157 (736) 18/25 (72) 
Female 1010 (40) 665/1537 (43) 41/149 (28) 43/157 (27) 7/25 (28) 
Marital status, no. (%)           
Unmarrieda 582/2501 (23) 323/1530 (21) 40/149 (27) 53/156 (34) 9/25(36) 
Married 1919/2501 (77) 1207/1530 (79) 109/149 (73) 103/156 (66) 16/25 (64) 
Transmission            
Injecting drug users (IDU) 263/2517 (10) 39/1537 (3) 5/149 (3) 86/157 (55) 16/25 (64) 
Sexualb 1863/2517 (74) 1270/1537 (83) 123/149 (83) 58/157 (37) 6/25 (24) 
Others/unknownc 391/2517 (16) 228/1537 (15) 21/149 (14) 13/157 (8) 3/25 (12) 
Age at ART initiation, year           
Mean (SD) 42 (14) 43 (14) 40 (13) 38 (8) 36 (9) 
Median (IQR) 39 (31-50) 40 (31-52) 38 (29-48) 37 (32-41) 37 (31-38) 
WHO HIV Clinical Stage, no. (%)           
Stage I/II 1986/2511 (79) 1215/1537 (79) 113/149 (76) 131/157 (83) 18/25 (72) 
Stage III/IV 525/2511  (21) 322/1537 (21) 36/149 (24) 26/157 (17) 7/25 (28) 
CD4, cells/µl           
Mean (SD) 302 (186) 316 (193) 308 (194) 309 (162) 306 (126) 
Median (IQR) 281 (177-388) 294 (180-412) 276 (165-412) 295 (186-379) 303 (239-368) 
<200 719/2402 (30) 420/1490 (28) 43/147 (29) 43/154 (28) 4/24 (17) 
≥200 1683/2402 (70) 1070/1490 (72) 104/147 (71) 111/154 (72) 20/24 (83) 
AST, U/L           
Mean (SD) 33 (27) 30 (24) 39 (31) 52 (38) 42 (24) 
Median (IQR) 27 (21-37) 26 (21-34) 30 (24-40) 42 (30-61) 36 (23-47) 
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ALT, U/L           
Mean (SD) 30 (27) 27 (21) 33 (22) 50 (42) 42 (18) 
Median (IQR) 23(16-35) 22 (15-32) 28 (18-38) 37 (23-63) 36 (33-54) 
Abbreviations: HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human immunodeficiency; AST = asparate aminotransferase; ALT 
= alanine transaminase; SD = standard deviation; IQR = interquartile range. 
aIncludes unmarried, divorced, and widowed. 
bIncludes heterosexual and homosexual categories. 
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Table 2 All-cause mortality since starting ART analyed both in a conventional Cox model and an extended Cox model  
Variable  
Conventional Cox model   Extended Cox model  
Original data 
 
Imputed datasets  Original data  Imputed datasets 
HR (95% CI) P   HR (95% CI) P   HR (95% CI) P   HR (95% CI) P 
Gender                        
Female 1 (Ref) 
 
1 (Ref) 
 
1 (Ref) 
 
1 (Ref) 
Male  1.35 (0.88-2.06) .169  1.25(0.91-1.71) .175  1.34 (0.88-2.05) .171  1.25(0.91-1.71) <.173 
Marital status                   1.00(1.00-1.00)   
Married 1 (Ref) 
 
1.00(1.00-1.00) (Ref) 
 
1 (Ref) 
 
1.00(1.00-1.00) (Ref) 
Unmarrieda 0.92 (0.60-1.42) .718 
 
1.08(0.78-1.48) 0.647 
 
0.91 (0.59-1.40) .666 
 
1.06(0.78-1.46) <.700 
Transmission        1.00(1.00-1.00)           1.00(1.00-1.00)   
 IDU 1 (Ref) 
 
1.00(1.00-1.00) (Ref) 
 
1 (Ref) 
 
1.00(1.00-1.00) (Ref) 
Sexualb 0.33 (0.17-0.65) .001  0.48(0.27-0.84) .011  0.33 (0.17-0.64) <.001  0.47(0.00-0.83) .010 
Others/unknownc 0.54 (0.25-1.14) .107 
 
0.68(0.37-1.26) .214 
 
0.52 (0.24-1.11) .092 
 
0.68(0.00-1.25) .208 
Baseline age 1.04 (1.02-1.05) <.0001   1.03(1.02-1.05) <.0001   1.04 (1.03-1.05) <.0001   1.04(1.02-1.05) <.0001 
Stage       1.00(1.00-1.00)           1.00(1.00-1.00)   
Stage I/II 1 (Ref) 
 
1.00(1.00-1.00) (Ref) 
 
1 (Ref) 
 
1.00(1.00-1.00) (Ref) 
Stage III/IV 2.13 (1.44 -3.17) <.001 
 
1.97(1.45-2.67) <.0001 
 
2.08 (1.40-3.11) <.001 
 
1.94(1.42-2.63) <.0001 
CD4, cells/µl 1.00 (1.00-1.00) <.0001   1.00(1.00-1.00) <.0001   1.00 (1.00-1.00) .006   1.00(1.00-1.00) <.001 
Infection       1.00(1.00-1.00)           1.00(1.00-1.00)   
HIV only 1 (Ref) 
 
1.00(1.00-1.00) (Ref) 
 
1 (Ref) 
 
1.00(1.00-1.00) (Ref) 
HBV-HIV  1.32 (0.73-2.40) .359  1.16(0.61-2.22) .644 
 
1.33 (0.73-2.41) .355 
 
1.15(0.61-2.2) .653 
HCV-HIV  0.71 (0.32-1.57) .399  1.00(0.43-2.32) .991 
 
0.69 (0.32-1.52) .352 
 
0.99(0.44-2.24) .977 
Triple infection 0.37 (0.05-2.84) .342  0.59(0.00-2.21) .426 
 
0.35 (0.05-2.66) .311 
 
0.57(0.15-2.20) .410 
AST, U/L 1.01 (1.01-1.02) <.0001   1.01(1.01-1.01) <.0001   1.01 (1.01-1.02) <.0001   1.01(1.01-1.01) <.0001 
ALT, U/L 0.99 (0.98-1.00) .049   0.99(0.98-1.00) .027   0.99 (0.98-1.00) .045   0.99(0.98-1.00) .022 
CD4*log(time)  -  -    -  -   1.00 (1.00-1.00) <.001   1.00(1.00-1.00) <.001 
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Abbreviations: HR= hazard ratio; 95%CI = 95% Confidence Interval; HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human immunodeficiency; 
AST = asparate aminotransferase; IDU=Injecting drug users; ALT = alanine transaminase; SD = standard deviation; IQR = interquartile range.                                                                                                                                                                                                                                                       
aIncludes unmarried, divorced, and widowed.                                                                                                                                                                                                                                                                           
bIncludes heterosexual and homosexual.                                                                                                                                                                                                                                                                         
cIncludes blood transfusion, mother-to-Child, and others/unknown.                                                                
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Discussion 
This is a large cohort study evaluating the coinfection of hepatitis virus with HIV from 
Yunnan province in China. Globally, it has been estimated that, of HIV-infected 
population, 5-20% have HBV and 5-15% have HCV infection [3]. We found 8% of 
HBV and 8%of HCV) coinfection, that both are within this range. As a matter of fact, 
the prevalence of HBV and HCV coinfection among Chinese HIV patients varies 
remarkably among different studies. The prevalence of HBV or HCV infection in our 
study was close to that reported in previous studies (HBV: 8.7%; HCV: 10.4%) [7, 
21], but much lower than other reports (HBV: 14.6%; HCV: 40%) [6, 22]. These 
phenomenon are probably attributed to the mode of acquisition, including childhood 
acquisition and adult transmission mode such as injecting drug practice and 
unprotected sex [8]. Consistently, our data (Table 1) have shown that injecting drug 
users (IDU) are associated with high prevalence of HCV infection and triple 
coinfection, and sexual transmission is related to a high prevalence of HBV infection 
in our cohort. 
Whether coinfection affects HIV patient survival remains under debating. In 
particular, there are substantial controversial data concerning coinfection of hepatitis 
virus on the overall survival of HIV patients receiving ART. By multivariate Cox 
analysis, we have demonstrated that coinfection has no significant relation to overall 
survival, consistent with the results of several previous studies [15, 21, 23, 24]. 
However, other studies have reported significant association between coinfection 
and patient survival, e.g. worse survival in patients with triple or HCV-HIV coinfection 
[7, 25-27]. These discrepancies are likely related to several factors, such as patient 
population, follow up time, and adjusted confounders. 
Finally, we assessed the correlation between coinfection and longitudinal 
changes of CD4 cell count receiving ART. Within 24 months of ART, patients with 
HBV or HCV coinfection and in particular with HIV mono-infection have increased 
CD4 cell count. Within 12 months of ART, patients with triple infection have a 
dramatic decline of CD4 cell count. However, the change after 12 months in this 
group is difficult to predict, because of limited patients by that time. In contrary, a 
previous study has reported no significant difference of CD4 cell count after ART 
between hepatitis virus coinfection and HIV only [7]. Of note, categorical variable of 
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CD4 (increase ≤30% and > 30%) was used rather than continuous CD4 values in 
their study. 
Nevertheless, there are some limitations in our study. First, we were not able to  
evaluate the longitudinal changes of viral load after long-term ART, because of the 
lacking of data. However, CD4 cell count, which serves as the most important 
indicator of immune function in patients with HIV infection, was analyzed throughout 
the study. Second, no data regarding specific liver diseases is available for these 
patients. Thus, the association between coinfection of hepatitis virus and liver 
disease among HIV-positive patients was not attainable. In other words, no 
significant association with overall survival observed in this study does not 
necessarily exclude the possible relation between coinfection and liver diseases. 
In conclusion, we found that sexual transmission, WHO clinical stage, age, CD4 
count, AST, and ALT are independent prognostic factors for overall survival in this 
large HIV cohort Yunnan province in China. Yet, coinfection with hepatitis virus has 
no  significant negative effect on the survival of HIV patients treated with 
antiretroviral therapy. Interestingly, constant increase of CD4 cell counts was 
observed among patients without coinfection of hepatitis virus receiving ART. These 
findings bear important implications for better management of hepatitis virus co-
infected HIV patients. 
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Methods  
Participants 
A cohort study was conducted by enrolling HIV patients at start of ART between 
2006 to 2016 in Zhaotong, Yunnan province, China. Patients were included from 
different areas of Zhaotong (a prefecture-level city), including Zhaoyang District, 
Ludian County, Qiaojia County, Yanjin County, Daguan County, Yongshan County, 
Suijiang County, Zhenxiong County, Yiliang County, Weixin County and Shuifu 
County. All patients were treated according to the national AIDS treatment criterial, 
ART drug resistance, individual health, and other relevant factors. Data were 
collected on demographic variables such as age, sex, marital status, and 
transmission category; and pathological variables such as liver enzyme indicators 
(AST and ALT), WHO clinical stage at baseline of ART initiation for each individual.                        
The institutional ethical committee of the First Affiliated Hospital of Kunming 
Medical University has approved this study. Informed consent was obtained from all 
individuals in this study. No personally identifiable information was seen and used in 
our analysis. All the methods of this study were performed in accordance with the 
guideline and regulation of the institutional ethical committee of the First Affiliated 
Hospital of Kunming Medical University. 
Laboratory tests 
Serum samples were used to detect HIV-1 using SD BIOLINE HIV Ag/Ab Combo 
Rapid (Standard Diagnostics, INC.; Korea) at the HIV testing outreach lab in the first 
people's hospital of Zhaotong. HIV-1-positive samples were screening for HIV 
antibodies with an enzyme-linked immunosorbent assay (Beijing WANTAI Biological 
Pharmacy Enterprise Co., Ltd.; China). Positive samples were subsequently 
transported to the central lab in Kunming within 12 hr. Western blot analysis (MP 
Diagnostics Co., Ltd.; Singapore) was performed for confirmation. Both HBV and 
HCV infections were tested by enzyme-linked immunosorbent assay (Xiamen Yingke 
Xinchuang Technology Co., Ltd.; China; Beijing WANTAI Biological Pharmacy 
Enterprise Co., Ltd.; China).  
Statistical Analysis 
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Standardized deviation (SD) and median with interquartile range (IQR) were 
computed for continuous variables and number with percentage for categorical 
variables. All of descriptive statistics were completed by dplyr package [16]. Missing 
values were firstly explored using Visualization and Imputation of Missing Values 
(VIM) package [17], which was shown in Supplementary Figures S1 and S2, and 
for the purpose of checking the sensitivity of inferences from Cox model, missing 
values were handled by Multiple Imputation (five complete datasets were 
constructed) by Chained Equations (MICE) package [18]. Survival analyses were 
done using survival package [19]. Kaplan-Meier survival curve was used for 
examining overall survival stratified by hepatitis virus status, with the statistical 
difference among groups assessed by Log-rank test. Furthermore, the assumption of 
proportional hazards was tested both statistically and graphically using function 
cox.zph from package of survival (Supplementary Table S1 and Figures S3). 
Prognostic factors for overall survival were further evaluated both in the conventional 
Cox model and the extended Cox model (addressing time-varying coefficients) for 
each original data and multiple imputed datasets. To be noted, covariates for 
inclusion in statistical model were based on prior research and biomedical 
importance [7, 13]. All statistical analyses were performed in R (version 3.4.0) [20]. 
Two sided P < .05 was considered significant. Finally, R code for performing 
statistical analyses in this study was provided in supplementary Figure S1. 
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Supplementary data 
 
 
 
Table S1 Testing proportional hazards assumption of conventional Cox model  
  rho chisq p 
Gender  
   Female    -    - (Reference) 
Male -0.024 0.071 0.790 
Age 0.115 1.995 0.157 
Marital status 
   Married    -    - (Reference) 
Unmarrieda 0.062 0.445 0.505 
Transmission  
   Injecting drug users (IDU)    -    - (Reference) 
Sexualb -0.145 2.334 0.127 
Others/unknownc -0.077 0.658 0.417 
WHO HIV Clinical Stage 
   Stage I/II    -    - (Reference) 
Stage III/IV -0.063 0.497 0.481 
CD4  0.262 10.775 0.001 
Infection 
   HIV only    -    - (Reference) 
HBV-HIV co-infection 0.015 0.027 0.870 
HCV-HIV co-infection -0.186 4.565 0.033 
Triple infection -0.015 0.029 0.864 
AST, U/L -0.166 1.962 0.161 
ALT, U/L 0.099 1.411 0.235 
GLOBALb NA 23.739 0.022 
Abbreviations:HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human immunodeficiency; AST = 
asparate aminotransferase; ALT = alanine transaminase; SD = standard deviation; IQR = interquartile 
range.                                                                                                                                                                                                                                                                                                                                                                                                              
aIncludes unmarried, divorced, and widowed.                                                                                                                                                                                                              
bIncludes heterosexual and homosexual.                                                                                                                                                                                                                          
cIncludes blood transfusion, mother-to-Child, and others/unknown.                                                                
rho indicates Pearson's correlation between the scaled Shoenfeld residuals and g(t) where g is a 
function of time, where transform= function(time) log (time) is used in cox.zph() function.                                                                                                     
 
 
 
 
 
Chapter 4 
 
 81 
 
 
A. Missing data exploration 
 
library(mice) 
library(VIM) 
 
mice::md.pattern(data) 
VIM::matrixplot(data) 
VIM::aggr(data,prop=TRUE,numbers=TRUE) 
 
mi.df <- mice (data,m=5,seed=12,printFlag=F) 
summary(mi.df) 
 
 
 
 
 
B. Build Cox model  
 
library(survival) 
 
# Conventional Cox model  
 
coxph_conventional <-
coxph(Surv(time,event)~gender+age+marital_status+transmission+WHO_stage+CD4+infection+AST
+ ALT, data) 
summary(coxph_conventional) 
 
 
# Testing proportional hazards assumption of conventional Cox model 
 
zp<- (cox.zph(coxph_conventional, transform=function(time) log(time+20)) 
 
# Ploting scaled schoenfeld residuals against transformed time for covariate of CD4 count in 
conventional Cox model fit 
plot (zp[7])   
abline (0,0) 
 
  
# Adding time-by-covariate interaction to Cox model 
 
coxph_timeByCovariate <- 
 coxph (Surv(time,event)~ 
CD4+tt(CD4)+gender+marital_status+transmission+WHO_stage+age+infection+ALT+ 
AST, data, tt=function(x,t,… x*log(t+20)) 
summary(coxph_timeByCovariate) 
 
 
Figure S1  R code used for performing missing value exploration & multiple imputation, and fitting 
Cox model 
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Supplementary Figure S2  Matrix plot of missing and non-missing values for all included patients.  
 
 
 
 
 
 
Chapter 4 
 
 83 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                   Coinfection of hepatitis virus and HIV 
 
84 
Supplementary Figure S3 Missing data pattern presented visually: (A) In the main body of text, "1" 
indicates non-missing value and "0" indicates missing value. pattern.   
The first column displays the number of patients with unique missing value pattern.  
For instance, 1750 patients have non-missing values, 36 patients have missing value for AST, etc..  
The last column shows the number of missing variables in the corresponding missing value. (B) The left 
 panel displays proportion of missing values for each variable. And the right panel  the same information as  
(A).  
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Figure S4 Plots of scaled Schoenfeld residuals against time for covariate of CD4 count in Cox model 
fit. The solid curve is a smoothing spline fit to the plot, with the broken lines representing a ± 2-
standard-error band around the fit; and the solid line is a horizontal line.   
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Figure S5 Scatterplot displaying the longitudinal changes of CD4 cell count at various time points of 
follow up. The boxplots represent interquartile range and medians.  
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Abstract  
 
Hepatocellular carcinoma (HCC) is an important cause of cancer-related death 
worldwide. Ethnical disparity in overall survival has been demonstrated for HCC 
patients in the United States (U.S.). We aimed to evaluate the contributors to this 
survival disparity. The SEER database was used to identify HCC patients from 2004 
to 2012. Kaplan-Meier curves and Cox proportional hazard models were used to 
evaluate overall survival by ethnicity and the contributors to ethnical survival 
disparity. A total of 33 062 patients were included: 15 986 Non-Hispanic Whites, 
6535 Hispanic Whites, 4842 African Americans, and 5699 Asians. Compared to 
Non-Hispanic Whites, African Americans had worse survival (HR, 1.18; 95%CI, 
1.14–1.23), while Asians had a better survival (HR, 0.85; 95%CI, 0.82–0.89), and 
Hispanic Whites had a similar survival (HR, 1.01; 95%CI, 0.97–1.05). Multivariate 
Cox analysis identified that tumor presentation- and treatment-related factors 
significantly contributed to the ethnical survival disparity. Especially, tumor size was 
the most important contributor (HR, 1.11; 95%CI, 1.07–1.16). There is no ethnical 
survival disparity in patients undergoing liver transplantation and sub-analysis of 
patients within the Milan criteria for liver transplantation demonstrated no significant 
survival disparity between African Americans and non-Hispanic Whites in 
transplantation adjustment analysis (HR, 1.23; 95%CI, 1.11–1.35 in non-adjustment 
analysis to HR, 1.05; 95%CI, 0.95–1.15 after adjustment). Finally, no important 
contributor to the superior overall survival in Asians was identified. In conclusion, 
poor tumor presentation at diagnosis, limited benefit from resection and restricted 
utilization of liver transplantation are important contributors to poorer survival of 
African Americans with HCC. 
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Introduction  
 Hepatocellular Carcinoma (HCC) is the fifth most common malignancy and the 
second leading cause of cancer-related death worldwide [1]. Ethnicity has been 
demonstrated to be related to the prognosis of HCC patients in the United States 
(U.S.) [2–5]. In general, African American ethnicity is associated with the poorest 
overall survival rate; whereas Asian ethnicity is associated with the best overall 
survival [3–5]. To improve the quality of health care for HCC patients, it is important 
to identify the factors affecting this ethnical disparity in overall survival rates (OS), 
and to compare their impacts.  
Several factors associated with tumor presentation at time of diagnosis, type of 
surgical treatment, and socioeconomic status (SES), have previously been studied 
with regard to ethnic disparity in OS for HCC patients. Previous literature has 
reported that African American patients have a more advanced, and Asian patients a 
less advanced tumor stage at the moment of diagnosis, compared to non-Hispanic 
white patients [6, 7]. Obviously, more advanced disease at time of diagnosis may 
affect OS. However, access to curative treatment options may also play a role. 
African American patients have been demonstrated to have less surgical treatment 
(resection or liver transplantation (LT)) than non- Hispanic white patients, and Asian 
patients are less likely to have transplantation but more likely to have hepatectomy 
than non-Hispanic white patients [6–8]. However, it should be noted that there have 
been inconsistent reports about treatment effects. Mathur et al [9] reported that after 
tumor ablation and hepatic resection, African American and Hispanic patients had 
the worst survival. Asian patients had better survival than white patients after 
ablation and similar survival after hepatectomy. After liver transplantation, there was 
no significant difference in survival by race/ethnicity [9]. On the other hand, several 
other studies have reported that African American patients have worse OS after liver 
transplantation than non-Hispanic white patients [3, 10]. Finally, socioeconomic 
status (SES) could be the potential driving factor for ethnical survival disparity as it 
can affect healthcare-utilization (early detection, treatment, and post-treatment 
quality of life) in cancer patients [11]. However, several studies have found that SES 
does not explain ethnic disparity in OS for HCC patients [11, 12]. 
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Inconsistencies in study results might be due to differences between the 
populations and study designs. Nevertheless, there are many socioeconomic and 
tumor-and treatment-related factors that may impact racial disparity in survival of 
HCC patients more or less, and as far as we know their influence on OS has not 
been compared [4]. In this study we describe the relative contributions of these 
factors to the ethnical disparity in OS for HCC patients, using The Surveillance, 
Epidemiology, and End Results (SEER) database. 
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Results 
Population  
Based on inclusion criteria, this study included a total of 33 062 patients who were 
diagnosed with HCC from 2004 to 2012 (Supplementary Figure 1). The population 
characteristics are summarized in Table 1. Among them, 15 986 (48%) were Non-
Hispanic Whites, 6535 (20%) were Hispanic Whites, 4842 (15%) were African 
Americans, and 5699 (17%) were Asians (Asian or Pacific Islander). Although not 
statistically significant, in comparison to other ethnicities, Asians had a higher 
average age (mean age: 63 years, IQR:55–73) than Non-Hispanic Whites (mean 
age: 62; IQR: 55–72) and African Americans (mean age: 59; IQR: 54–64). 
Additionally, African Americans were more likely to be diagnosed with large tumor 
(tumor size > 5cm) than Non-Hispanic Whites, and vice versa. For example, among 
African Americans 38% had large tumor and 17% had small tumor; among Non-
Hispanic Whites 34% had large tumor and 22% had small tumor (p < .0001). 
Ethnical disparity in overall survival in overall HCC population  
Figure 1 displays the overall survival (OS) rates among different ethnical 
populations. The median survival was 8 months (95%CI: 7.6–8.4), 9 months (95%CI: 
8.4–9.6), 6 months (95%CI:5.5–6.5), and 13 months (95%CI: 12.0–14.0) for Non-
Hispanic White, Hispanic White, African American, and Asian patients, respectively. 
1-year and 3-year survival rates were 44% and 24%, 45% and 23%, 38% and 18%, 
and 51% and 31% for Non- Hispanic White, Hispanic White, African American, and 
Asian patients, respectively. Therefore, Hispanic White and Non-Hispanic White 
patients had similar survival rates. Asian patients displayed the best OS, and African 
American patients had the poorest OS. Specifically, there was significant “negative” 
survival disparity between African American and Non-Hispanic White patients (P < 
.0001), and “positive” survival disparity between Asian and White patients (P < 
.0001). 
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Figure 1 The Kaplan-Meier survival curves showing ethnical survival disparities 
 
To determine the importance of several demographic-, tumor- and treatment-related 
factors for ethnical survival disparity, we performed multivariate analyses, and then 
observed the change of hazard ratios (HRs). Figure 2 shows a forest plot presenting 
results from multivariate Cox models for all ethnical groups in the overall population 
(reference: Non-Hispanic White). No significant difference was observed between 
Hispanic White and Non-Hispanic White both in univariate analysis (HR, 1.01; 
95%CI, 0.97–1.05) and multivariate analysis (HR, 0.98; 95%CI, 0.95–1.02). 
However, with respect to African American patients, we noticed some remarkable 
changes in survival disparity in Cox models. The initial survival disparity between 
African American and Non-Hispanic White (HR, 1.18; 95%CI, 1.14–1.23) did not 
change much when we adjusted demography-related variables. However, it was 
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affected by tumor size (HR, 1.11; 95%CI, 1.07–1.16), which indicated that the 
increased occurrence of large tumor in African Americans was associated with their 
poor survival. The other tumor-related variables that we studied did not significantly 
change the survival disparity any further. After additional adjustment for treatment-
related factors, the significant survival disparity between African Americans and Non-
Hispanic Whites became non-significant (HR, 1.03; 95%CI, 0.99–1.07). Therefore, 
we conclude that tumor size and treatment contributed largely to the survival 
disparity between African American and Non-Hispanic White patients. When 
comparing Non-Hispanic Whites to Asian patients, the latter population displayed a 
significantly better survival (HR, 0.85; 95%CI, 0.82–0.89), which remained constant 
from univariate analysis (HR, 0.85; 95%CI, 0.82–0.89) to multivariate analysis (HR, 
0.86; 95%CI, 0.83–0.90). In other words, we did not identify the contributors to 
superior survival in Asian patients.  
Since, for a large group of patients fibrosis scores were unavailable in the full 
SEER dataset, which may present a bias with respect to the survival data, we further 
analyzed a subset of patients for which this fibrosis score was available (n = 7070, 
characteristics in Supplementary Table 1). Supplementary Figure 3 demonstrates 
that this subpopulation African Americans also had a poorer survival than Non-
Hispanic Whites (HR, 1.19; 95%CI, 1.08–1.31). This survival disparity in multivariate 
analysis was again affected by tumor size; the factor large tumor size was 
associated with poor survival (HR, 1.10, 95%CI, 1.00–1.22). 
 
Ethnical disparity in overall survival in patients stratified by treatment 
We further explored the survival patterns among ethnicities in subgroups stratified by 
treatment: patients treated with tumor destruction (radiofrequent ablation / 
percutaneous ethanol injection (PEI) etc.) (9% of total), those that had surgical 
resection (9% of total), and those that have had liver transplantation (6% of total) 
(Table 1). As for the patients who underwent tumor destruction, both African 
Americans and Hispanic Whites showed non-significant survival difference 
compared to Non-Hispanic Whites. Asians had a much higher survival rate than 
Non- Hispanic Whites (HR, 0.71; 95%CI, 0.61–0.82) and no specific reason was 
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found for this disparity (Figure 3A). For patients receiving surgical resection, we 
found significantly lower survival rates in Hispanic Whites (HR, 1.20; 95%CI, 1.00–
1.42) and African Americans (HR, 1.27; 95%CI, 1.08–1.50) than in Non-Hispanic 
Whites. Demographic and tumor-related factors negatively influenced survival in 
Hispanic Whites but for African Americans no such contribution could be identified 
among the various Cox models. Of interest, after surgical resection Asians did not 
have significantly higher survival rates than Non-Hispanic Whites (Figure 3B). 
Interestingly, no significant ethnical difference in survival was detected in patients 
after liver transplantation (Figure 3C). 
Ethnical survival disparity in patients eligible for liver transplantation 
To further explore the impact of liver transplantation on ethnical survival disparity, we 
performed survival analyses in a subgroup of patients who met the Milan criteria for 
liver transplantation (1 nodule ≤ 5 cm and max 3 nodules ≤ 3cm and no signs of 
vascular invasion/ extrahepatic spread). Table 2 describes the characteristics for 
those patients. The patients receiving liver transplantation accounted for 15% of total 
patients “within Milan”; 19% of Non-Hispanic Whites (n = 802), 11% of African 
Americans (n = 111), 13% of Hispanic Whites (n = 232), and 10% of Asians (n = 
137) (P < .0001). The survival rates are displayed in Figure 4. Compared to Non-
Hispanic Whites, Hispanic White patients exhibited a poorer survival (HR, 1.12; 
95%CI, 1.03–1.22), which was improved when adjusting for tumor-related factors but 
became not significant after adjusting for liver transplantation. Also, African American 
patients displayed a poorer survival (HR, 1.23; 95%CI, 1.11–1.35), and their 
outcome was improved when adjusting tumor-related variables. But especially when 
transplantation status was adjusted, the survival discrepancy disappeared (HR, 1.05; 
95%CI, 0.95–1.15). Finally, the superior survival remained constant for Asian 
patients from crude analysis to adjustment analyses. 
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Figure 2 Forest plot presenting the estimated HR’s of ethnicity on overall survival  from multivariate Cox models for all ethnical groups (reference: Non-
Hispanic White). The first HR is the crude effect followed by HR after adjustment entering covariates in a forward stepwise manner (LR): age, marriage, 
gender, income, education, tumor size, stage, grade, AFP, number of lesion, metastatic status, fibrosis, lymph node status, vascular invasion, and treatment. 
Block 1 included race, block 2 included age, gender, marital status, education, income, poverty, residence, block 3 included grade, stage, number of lesion, 
tumor size, lymph node status, vascular invasion, metastatic status, AFP, and fibrosis, and block 4 included treatment.  
Racial disparity in overall survival in patients with hepatocellular carcinoma  
 
96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3  Forest plot presenting the estimated HR’s of ethnicity on overall survival from multivariate 
Cox models for all ethnical groups stratified by treatment (reference: Non-Hispanic White). Forward 
stepwise method was used to study the changes of HR of ethnicity after entering the following 
covariates: in the stratum A. No treatment: age race, marriage, gender, income, tumor size, stage, 
grade, AFP, number of lesion, metastatic status, fibrosis, vascular invasion, and lymph node 
involvement. In the stratum B. Destruction: race, age, education, stage, tumor size, number of lesion, 
AFP, grade, and vascular invasion. In the stratum C. Resection: race, gender, age, marriage, stage, 
grade, tumor size, number of lesion, AFP, fibrosis, and vascular invasion. And in the stratum D. 
Transplantation: race, vascular invasion, stage, and tumor size.    
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 Figure 4 Forest plot presenting the estimated HR’s of ethnicity on overall survival from multivariate 
Cox models for all ethnical groups who met Milan criteria (reference: Non-Hispanic white). The first 
HR is the crude effect followed by HR after adjustment entering covariates in a forward stepwise 
manner (LR): age, marriage, gender, education, grade, tumor size, AFP, fibrosis, lymph node status, 
number of lesion, and transplantation. Block 1 included race, block 2 included age, gender, marital 
status, education, income, poverty, residence, block 3 included grade, stage, number of lesion, tumor 
size, lymph node status, vascular invasion, metastatic status, AFP, and fibrosis, and block 4 included 
treatment. 
 
 
 
 
 
 
Racial disparity in overall survival in patients with hepatocellular carcinoma  
 
Table 1 Characteristics of all patients by ethnicity  
 
Characteristics Total  
Ethnicity         
Non-Hispanic 
White Hispanic White 
African 
American Asian P Value 
Patients 
      No. % 33 062 15 986 (48) 6535 (20) 4842 (15) 5699 (17) 
 Age           <.0001a 
Mean [SD],y 63 [12] 63 [11] 62 [12] 60 [10] 63 [13] 
 Median [IQR],y 61 [55-71] 62 [55-72] 60 [53-70] 59 [54-64] 63 [55-73] 
 Gender (%)           <.0001b 
Male 25 728 (78) 12 698 (79) 5061 (77) 3779 (78) 4190 (74) 
 Female 7334 (22) 3288 (21) 1474 (23) 1063 (22) 1509 (27) 
 Marital status (%)           <.0001a 
Married 16937(51) 8151(51) 3285(50) 1607(33) 3894(68) 
 Unmarried 14775(45) 7158(45) 3003(46) 2999(62) 1615(28) 
 Unknown 1350(4) 677(4) 247(4) 236(5) 190(3) 
 Education (%)c           <.0001b 
Mean [SD] 16 [6] 15 [6] 19 [6] 16 [5] 16 [5] 
 Median [IQR] 15 [12-22 ] 14 [11-20] 20 [14-23] 15 [12-18] 14 [12-23] 
 Poverty (%)           <.0001a 
Mean [SD] 16 [5] 15 [5] 17 [4] 18 [6] 14 [4] 
 Median [IQR] 16 [12-18] 14 [12-18] 18 [13-18] 18 [13-23] 13 [10-18] 
 Income (%)           <.0001a 
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Mean [SD] 59619 [14401] 58 600 [14690] 59478 [12533] 53924 [13423] 67477 [13132] 
 
Median [IQR] 
55910 [50588-
69710 ] 
56490  [48260-
66520] 
55910 [54090-
62960] 
55060 [41180-
61260] 
67180 [55910-
75600] 
 Residence (%)           <.0001b 
Rural  2592(8) 1957(12) 255(4) 265(5) 115(2) 
 Urban 30470(92) 14029(88) 6280(96) 4577(95) 5584(98) 
 Lesion number (%)           .002b 
Single 32015(97) 15438(97) 6373(98) 4697(97) 5507(97) 
 Multiple 1047(3) 548(3) 162(2) 145(3) 192(3) 
 Grade (%)           <.0001b 
Well differentiated 4325(13) 2209(14) 883(14) 598(12) 635(11) 
 Moderately differentiated 5377(16) 2664(17) 896(14) 797(16) 1020(18) 
 Poorly differentiated 2854(9) 1358(8) 466(7) 438(9) 592(10) 
 Undifferentiated 281(1) 140(1) 43(1) 39(1) 59(1) 
 Unknown 20225(61) 9615(60) 4247(65) 2970(61) 3393(60) 
 Stage (%)           <.0001b 
Localized 16143(49) 7822(49) 3304(51) 2175(45) 2842(50) 
 Regional 9618(29) 4573(29) 1849(28) 1473(30) 1723(30) 
 Distant 5201(16) 2466(15) 984(15) 906(19) 845(15) 
 Unstaged 2100(6) 1125(7) 398(6) 288(6) 289(5) 
 Tumor size (cm),%           <.0001b 
<3 6693(20) 3499(22) 1335(20) 808(17) 1051(18) 
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3-5 7519(23) 3613(23) 1601(24) 1030(21) 1275(22) 
 >5 12184(37) 5497(34) 2370(36) 1847(38) 2470(43) 
 Unknown 6666(20) 3377(21) 1229(19) 1157(24) 903(16) 
 Lymph node involvement (%)           <.0001b 
No lymph node 25833(78) 12380(77) 5091(78) 3753(78) 4609(81) 
 Lymph node 2272(7) 1239(8) 351(5) 401(8) 281(5) 
 Unknown 4957(15) 2367(15) 1093(17) 688(14) 809(14) 
 Vascular Invasion (%)           <.0001b 
No Vascular Invasion 16749(51) 8187(51) 3412(52) 2297(47) 2853(50) 
 Vascular Invasion 13467(41) 6269(39) 2569(39) 2137(44) 2492(44) 
 Unknown 2846(9) 1530(10) 554(8) 408(8) 354(6) 
 Metastatic status (%)           <.0001b 
No metastasis 25038(76) 12119(76) 4937(76) 3579(74) 4403(77) 
 Metastasis 5154(16) 2469(15) 989(15) 882(18) 814(14) 
 Unknown 2870(9) 1398(9) 609(9) 381(8) 482(8) 
 AFPd (%)           <.0001b 
Positive 19366(59) 8672(54) 3928(60) 3221(67) 3545(62) 
 Negative 5705(17) 3002(19) 1186(18) 546(11) 971(17) 
 Borderline 74(0) 48(0) 8(0) 10(0) 8(0) 
 Unknown 7917(24) 4264(27) 1413(22) 1065(22) 1175(21) 
 Fibrosis (%)           <.0001b 
None to moderate fibrosis 1622(5) 723(5) 236(4) 220(5) 443(8) 
 
Chapter 5 
 
 
101 
Severe fibrosis or cirrhosis 5448(16) 2678(17) 1209(19) 709(15) 852(15) 
 Unknown 25992(79) 12585(79) 5090(78) 3913(81) 4404(77) 
 Treatment (%)           <.0001b 
None 24646(75) 11672(73) 5178(79) 3850(80) 3946(69) 
 Tumor destruction 3102(9) 1544(10) 596(9) 368(8) 594(10) 
 Surgical resection 3002(9) 1364(9) 349(5) 406(8) 883(15) 
 Liver transplantation  2016(6) 1221(8) 374(6) 178(4) 243(4) 
 
Unknown 296(1) 185(1) 38(1) 40(1) 33(1)   
 a one-way ANOVA test 
  b Pearson Chi-Square  
 c Indicates the percentage of adults aged ≥ 25 years who had < 12 years of education. 
 d AFP positive indicates AFP >15 ng/ml.  
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Table 2 Characteristics of the patients within Milan criteria  
 
Characteristics Total  
Ethnicity       
Non-Hispanic 
White Hispanic White 
African American 
Asian P Value 
Patients 
      No. % 8 524 4290 (50) 1779 (21) 1056 (12) 1399 (16) 
 Age           <.0001 
Mean [SD],y 61 [10] 61 [10] 60 [10] 60 [9] 64 [11] 
 Median [IQR],y 60 [54-68] 60 [55-67] 59 [53-67] 59 [55-64] 63 [55-72] 
 Gender (%)           <.0001 
Male 6425 (75) 3380(79) 1319(74) 791(75) 935(67) 
 Female 2099 (25) 910(21) 460(26) 265(25) 464(33) 
 Marital status (%)           <.0001 
Married 4471(52) 2223(52) 896(50) 379(36) 973(70) 
 Unmarried 3732(44) 1893(44) 825(46) 625(59) 389(28) 
 Unknown 321(4) 174(4) 58(3) 52(5) 37(3) 
 Education            <.0001 
Mean [SD] 16 [6] 15 [6] 19 [6] 16 [5] 16 [5] 
 Median [IQR] 15 [12-22] 14 [11-19] 18 [14-23] 15 [12-16] 14 [13-20] 
 Poverty            <.0001 
Mean [SD] 15 [5] 15 [5] 16 [5] 18 [6] 14 [4] 
 Median [IQR] 15 [12-18] 14 [12-18] 18[13-18] 18 [13-21] 13 [10-18] 
 Income            <.0001 
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Mean [SD] 60176 [14217] 58775 [14214] 60168 [12703] 54675 [13422] 68633 [13069] 
 
Median [IQR] 
56530 [51380-
72110] 
56530 [48510-
65590] 
55910 [54090-
63360] 
55060 [41180-
62000] 
72110 [55910-
75600] 
 Residence (%)           <.0001 
Rural  585(7) 468(11) 60(3) 41(4) 16(1) 
 Urban 7939(93) 3822(89) 1719(97) 1015(96) 1383(99) 
 Lesion number (%)           .100 
Single 8309(97) 4170(97) 1747(98) 1033(98) 1359(97) 
 Multiple 215(3) 120(3) 32(2) 23(2) 40(3) 
 Grade (%)           <.0001 
Well differentiated 1457(17) 766(18) 293(16) 176(17) 222(16) 
 Moderately 
differentiated 
1582(19) 807(19) 270(15) 213(20) 292(21) 
 Poorly differentiated 461(5) 230(5) 79(4) 49(5) 103(7) 
 Undifferentiated 39(0) 20(0) 7(0) 3(0) 9(1) 
 Unknown 4985(58) 2467(58) 1130(64) 615(58) 773(55) 
 Stage (%)           .013 
Localized 8228(97) 4128(96) 1728(97) 1009(96) 1363(97) 
 Regional 295(3) 162(4) 51(3) 46(4) 36(3) 
 Distant 1(0) 0(0) 0(0) 1(0) 0(0) 
 Tumor size (cm),%           < .001 
<3 4465(52) 2348(55) 901(51) 524(50) 692(49) 
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3-5 4059(48) 1942(45) 878(49) 532(50) 707(51) 
 Lymph node involvement 
(%) 
          .001 
No lymph node 8173(96) 4099(96) 1706(96) 1004(95) 1364(97) 
 Lymph node 149(2) 92(2) 19(1) 25(2) 13(1) 
 Unknown 202(2) 99(2) 54(3) 27(3) 22(2) 
 Vascular Invasion (%)           NA 
No Vascular Invasion 8524(100) 4290(100) 1779 (100) 1056 (100) 1399 (100) 
 Metastatic status (%)           NA 
No metastasis 8524(100) 4290(100) 1779 (100) 1056 (100) 1399 (100) 
 AFP (%)           <.0001 
Positive 4629(54) 2126(50) 985(55) 682(65) 836(60) 
 Negative 2176(26) 1196(28) 482(27) 175(17) 323(23) 
 Borderline 21(0) 15(0) 2(0) 2(0) 2(0) 
 Unknown 1698(20) 953(22) 310(17) 197(19) 238(17) 
 Fibrosis (%)           <.0001 
None to moderate 
fibrosis 
523(6) 253(6) 59(3) 68(6) 143(10) 
 Severe fibrosis or 
cirrhosis 
2139(25) 1081(25) 469(26) 261(25) 328(23) 
 Unknown 5862(69) 2956(69) 1251(70) 727(69) 928(66) 
 Therapy (%)           <.0001 
None 4478(53) 2167(51) 1103(62) 604(57) 604(43) 
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Tumor destruction 1746(20) 864(20) 320(18) 202(19) 360(26) 
 Surgical resection 980(11) 432(10) 120(7) 133(13) 295(21) 
 Liver transplantation  1282(15) 802(19) 232(13) 111(11) 137(10) 
 Unknown 38(0) 25(1) 4(0) 6(1) 3(0)  
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Discussion  
Since HCC related mortality continues to increase in the US, the ethnical disparities 
in overall survival has attracted attention [13]. Many efforts have been devoted to 
exploring the reasons behind this phenomenon [4, 14] for a better understanding of 
its contributors, which shall help us to determine which interventions could reduce 
this disparity.  
We have confirmed the ethnical survival disparity in overall survival that has 
previously been reported by others [3–6, 9]. We demonstrated how tumor-related 
and treatment-related factors contribute strongly to survival disparity between African 
American and Non-Hispanic White patients. 
As demonstrated in previous studies, compared to non-Hispanic Whites we 
found a poor survival in African Americans and a good survival in Asian patients [4, 
7, 9, 12, 15, 16]. Our results demonstrate that increased presence of large tumor 
size was associated with poor survival in African Americans. Tumor size is 
considered as an important prognostic determinant in several HCC staging systems 
such as the TNM classification [17], the Barcelona Clinic Liver Cancer (BCLC) 
staging system [18], and the Hong Kong Liver Cancer (HKLC) classification [19]. 
Although previous studies have reported the significant differences in tumor size in 
HCC patients stratified by race and proposed it as a predictor of prognosis for HCC 
patients [4, 7, 9, 12, 15, 16], our study has demonstrated that tumor presentation 
indeed is the dominant contributor to the poor OS of African Americans. Such a clear 
dominant factor could not be demonstrated for Hispanic-Whites and Asians. In the 
former population demographic factors contributed to OS to some extent, but again 
presentation-related factors were shown to  be the dominant contributors. Stage of 
liver disease as represented by fibrosis score did not significantly impact the 
observed survival disparities, as in a sub-analysis of patients of which these data 
were available tumor size remained a major confounder. 
Consistent with previously studies, we found superior OS in Asians. Marital 
status affected HRs to some extent, and in our population Asians showed the 
highest percentage of marriage: up to 70% (P < .0001). Multiple studies have shown 
that being married is associated with more favorable survival for various cancer 
types [20–23] and this also appears to be the case in Asian HCC patients. 
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Treatment related factors also contributed to ethnical survival differences. As 
reported by others [9] African Americans displayed the poorest response to 
resection. We cannot explain this finding based on our data. African Americans were 
previously reported to have a longer waiting time period before surgery [12], which 
may affect the severity of their liver disease and consequently the chance on 
complications after surgery. However, this information was not available for us to 
study. 
We speculate that there is an impact of the etiology of liver disease on both the 
observed overall survival disparities and the discrepancies found in relation to 
treatment modality. The cause of liver disease in the majority of Asian HCC patients 
is chronic HBV infection; whereas in African Americans and non-Hispanic Whites 
chronic HCV infection, non-alcoholic fatty liver disease (NAFLD) and alcohol abuse 
are more common [24]. HBV infection is well manageable whereas HCV infection 
(before the DAA era) would have been progressive after resection or destruction. 
NAFLD is associated with obesity and diabetes and both can potentially lead to 
serious comorbidity [25], and alcohol abuse may have continued or recurred. 
Differences in etiology of underlying liver disease or (their impact on) comorbidity as 
contributors to the observed survival disparities after resection could not be studied 
since these data were not present in our database. 
Interestingly, no significant ethnical survival difference was observed after liver 
transplantation. These results do not match the study by Ananthakrishnan et al. [10], 
who reported that African American patients benefitted less from transplantation than 
Non-Hispanic Whites, using a United Network for Organ Sharing database [10]. 
However, our findings are in line with the data reported by Mathur et al [9], who also 
studied the SEER-database [9]. Therefore, these inconsistencies may be due to 
different patient populations analyzed. Although, Artinyan et al also used SEER data 
to report poorer survival after transplantation for African Americans [3], we believe 
that the population described in this particular study which included patients with 
diagnostic year as early as 1973 until 2004, is significantly different from our study 
population since implementation of the Milan criteria for liver transplantation in 
clinical practice only occurred after year of 1996 [26]. Therefore, differences in 
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eligibility criteria for liver transplantation may explain the differences in results 
between our and their study. 
We next explored a potential role for receiving liver transplantation on ethnical 
survival disparity. This issue has been discussed extensively over the years [6–8]. 
Several studies have demonstrated limited access to transplantation for African 
American patients, and indeed also in our study African Americans eligible for liver 
transplantation received this potentially curative treatment less frequently than non-
Hispanic Whites. But as also reported before, so did Asian HCC patients [8–10, 12, 
27–30]. Some studies have suggested that disparity in receiving transplantation may 
have contributed to ethnical disparity in survival [4, 9]. To determine the impact of 
undergoing liver transplantation on ethnical differences in survival, we analyzed the 
subgroup of patients who met the Milan criteria. Compared to Non-Hispanic Whites, 
Hispanic White and African American patients exhibited a poorer survival, and 
indeed their survival discrepancy disappeared after adjusting transplantation status. 
Asians “within Milan” on the other hand have better outcome which is unaffected by 
the factor liver transplantation. These patients have been shown to receive resection 
more often than liver transplantation and more often than any other race [7], and this 
is confirmed in our study. Since most of the Asian cases are likely HBV related [24] 
and may therefore have relatively preserved underlying liver function, more Asians 
can tolerate liver resection. It probably explains the small impact of transplantation 
on their survival. Of note, we could not identify a significant contributing role for 
socioeconomic or demographic factors to the ethnic survival discrepancy in this 
subgroup, suggesting that these factors may not determine access to 
transplantation. Indeed, whether or not to transplant is a complex decision making 
process that involves evaluation of etiology of liver disease, comorbidity, social 
context etc. and as said, these factors could not all be analyzed in our study. 
Our work has some limitations. Firstly, since our study is retrospective in 
nature, it holds the known biases associated with this type of study. Secondly, as 
mentioned the level of clinical detail available to us does not capture significant 
details that may affect the use of surgical therapy or survival, such as medical 
comorbidities, presence of chronic liver disease and its etiology, and information on 
the details of all treatments received. Thirdly, the county-level socioeconomic data 
may not fully capture the economic, educational, and social factors for individual 
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patients. Lack of social support, density of specialists within a region, hospital 
volume, distance to care, and other unmeasured confounders may have influenced 
access to therapies. Lastly, the effects of sorafenib or TACE on ethnical survival 
difference could not be studied since SEER has no specific coding for these 
treatment modalities. Nevertheless, to our knowledge, our analysis represents the 
most comprehensive study on ethnic differences in survival for HCC patients in the 
US. 
In conclusion, we have confirmed the ethnical disparities in overall survival of 
HCC patients in the US. Poor tumor-presentation at diagnosis, poor response to 
resection, and limited utilization of transplantation all play essential roles in the 
poorer survival of African Americans compared to other races. Asian patients have 
superior survival, but after liver transplantation ethnic disparity in survival is absent. 
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Methods  
Patients selection  
This study was performed using data from the Surveillance, Epidemiology, and End 
Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database (version 
8.2.1). The procedure for selecting the patients for the cohort is shown in 
Supplementary Figure 1. Briefly, these patients were diagnosed between 2004 and 
2012. We included the following ethnicities: Non-Hispanic White, Hispanic White, 
African American, and Asian (Asian/Pacific Islander). Among the Asian population in 
this study, 41.4% (2360/5699) were East Asians, 3.8% (219/5699) were South 
Asians, 39.2% (2233/5699) were Southeast Asians, and 15.6% were other Asians 
(887/5699). Native American (American Indian/Alska native) were excluded from our 
study. SEER Vital status recode (study cutoff used) variable was used to define the 
status of patients after the last follow-up date: death and alive. The survival time 
months variable, starting from diagnosis to last follow-up, was used for extracting 
information on patients’ survival time. The follow-up cut-off date was December 31, 
2012. Among the overall population, we selected patients within Milan criteria: one 
lesion ≤ 5 cm or up to 3 lesions each with diameter ≤ 3 cm; no extra-hepatic 
involvement; and no vascular invasion. 
Definition  
SEER Staging (also called Summary Staging) was used to define HCC stage: 
localized, regional, and distant. SEER Staging is the most basic way of categorizing 
how far a cancer has spread from its point of origin, as it combines the most precise 
clinical and pathological documentation of the extent of disease (http://training. 
seer.cancer.gov/ss2k/staging/). The detailed SEER Staging for HCC is documented 
in the “SEER Summary Staging Manual”. For example, localized HCC indicates the 
cancer confined to one lobe with or without vascular invasion, or multiple 
nodules/tumors confined to one lobe. 
HCC therapies were categorized into groups based on data available in SEER 
database: none, local tumor destruction, surgical resection, and liver transplantation 
(LT). None indicated: without any intervention such as local tumor destruction, 
surgical resection, or liver transplantation. Local tumor destruction included: 
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photodynamic therapy (PDT), electrocautery, cryosurgery, laser, PEI, heat-radio-
frequency ablation (RFA). Since SEER has no specific coding for chemotherapy 
(sorafenib) or chemoembolization (TACE), they were not specified as such in SEER 
database. Resection included wedge, segmental resection, and lobectomy. 
“Unknown” means uncertainty about whether surgery was performed or what type of 
surgery was done. 
The following SES related variables were included: education (the percentage 
of adults aged ≥ 25 years who < 12 years of education), poverty (the percentage of 
individuals living below the poverty line), and income (median annual household 
income). These variables were used as continuous variables in this study. According 
to the definitions of Country Attributes in SEER data, the higher values of the 
variables of education and poverty are, the lower the values of SES are. Please see 
“http:// seer.cancer.gov/seerstat/variables/countyattribs/#08–12” for details. 
Statistical analysis 
Standardized deviation (SD), and median with interquartile range (IQR) for 
continuous variables, and whole number with percentage for categorical variables. 
One-way ANOVA was used to compare groups for continuous variables. Pearson 
Chi-Square was used for comparing groups for categorical variables. Crude (non-
adjustment) survival analysis (Kaplan-Meier curve) was first used to display the 
overall observed ethnical survival differences. Hazard ratio (HRs) and 95% CIs were 
calculated to evaluate the prognostic power of variables in survival. The included 
variables were divided into three categories:1) demographic variables, including 
race, age, SEER site, gender, marital status, education, income, poverty, residence; 
2) presentation-related variables, including grade, stage, number of lesion, tumor 
size, lymph node involvement (yes or no), vascular invasion (yes or no), metastatic 
status (yes or no), AFP (Alpha-fetoprotein), and fibrosis degree (none to moderate 
fibrosis; several fibrosis or cirrhosis); and 3) treatment-related variables, including 
treatment presenting with categories — no treatment, tumor destruction, resection, 
and transplantation. For the procedure of multivariate cox model, race was entered 
as block 1, the remaining demographic variables were entered as block 2 (including 
age, gender, marital status, education, income, poverty, residence), presentation-
related variables were entered as block 3 (including tumor size, stage, grade, 
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number of lesion, lymph node status, vascular invasion status, metastatic status, 
AFP, and fibrosis staging), and finally treatment-related variable was entered as 
block 4. All analysis were stratified on SEER site to adjust for any heterogeneity 
between sites. Regarding block 2 and 3, the covariates were entered in a forward 
stepwise manner using the Likelihood Ratio test ( LR ) to describe their impact on 
survival. The changes in the HR’s of African Americans, Hispanic White and Asian 
versus Non-Hispanic White after the stepwise adjustment of the covariates are 
shown in forest plots. There were some missing values for several categorical 
variables in our study. As we did not find any significant differences from the analysis 
of all cases and the cases with known values, we treated the missing values (with 
“unknown” label shown in Tables 1–2) as a separate subcategory. Data preparation 
and forest plot were done in R (version 3.3.1). Statistical analyses was performed in 
SPSS (version 21); syntax shown in Supplementary Figure 2. P < .05 (two tailed 
sides) was considered as significant. 
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Supplementary Data  
 
 
 
 
Supplementary Figure S1 Flowchart displaying the  selection procedure of HCC cases in SEER 
database.  
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COXREG Time  
/STATUS=Vital(1)  
/STRATA SEER_Site (SEER site was stratified for all analysis)  
/CONTRAST (Race)=INDICATOR(1) 
/CONTRAST (Gender)=INDICATOR(1) 
/CONTRAST (Marriage)=INDICATOR(1) 
/CONTRAST (TumorSize)=INDICATOR(1) 
/CONTRAST (Stage)=INDICATOR(1) 
/CONTRAST (Grade)=INDICATOR(1) 
/CONTRAST (LesionNumber)=INDICATOR(1) 
/CONTRAST (LymphNode)=INDICATOR(1) 
/CONTRAST (Vascular)=INDICATOR(1) 
/CONTRAST (Metastasis)=INDICATOR(1) 
/CONTRAST (AFP)=INDICATOR(1) 
/CONTRAST (Fibrosis)=INDICATOR(1) 
/CONTRAST (Surgery)=INDICATOR(1) 
/METHOD=ENTER  Race 
/METHOD=FSTEP(lr)   Age Gender Marriage Education Income Poverty Residence   
/METHOD =FSTEP(lr) TumorSize Stage Grade LesionNumber  LymphNode  Vascular Metastasis 
AFP Fibrosis  
/METHOD=FSTEP(lr) Treatment 
/PRINT=CI(95) 
/CRITERIA=PIN(.05) POUT(.10) ITERATE(20).  
Supplementary Figure S2  SPSS syntax for performing multivariate analysis in this study 
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Supplementary Figure S3 Forest plot presenting the estimated HR’s of ethnicity on overall survival from multivariate Cox models for all ethnical groups with 
available fibrosis score (reference: Non-Hispanic white). The first HR is the crude effect followed by HR after adjustment entering covariates in a forward 
stepwise manner (LR) : age, marriage, gender, education, grade, tumor size, AFP, fibrosis, lymph node status, number of lesion, and transplantation. Block 1 
included race, block 2 included age, gender, marital status, education, income, poverty, residence, block 3 included grade, stage, number of lesion, tumor 
size, lymph node status, vascular invasion, metastatic status, AFP, and fibrosis, and block 4 included treatment. 
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Supplemental Table S1 Characteristics of the patients with known fibrosis value stratified by ethnicity. 
 
Characteristics Total  
Ethnicity         
Non-Hispanic 
White Hispanic White 
African 
American Asian P Value 
Patients 
      No. % 7070  3401 (48) 1445(20) 929 (13) 1295(18) 
 Age           <.0001a 
Mean [SD],y 61[10] 61 [10] 60 [10] 60 [8] 62 [12] 
 Median [IQR],y 60[55-67] 60 [55-67] 59 [53-66] 59 [55-64] 62 [54-71] 
 Gender (%)           <.0001b 
Male 5620 (80) 2783 1141 723 973 
 Female 1450 (20) 618 304 206 322 
 Marital status (%)           <.0001a 
Married 3723 (53) 1743 747 318 915 
 Unmarried 3153 (45) 1574 655 578 346 
 Unknown 194(3) 84 43 33 34 
 Education (%)           <.0001b 
Mean [SD] 16 [6] 15 [6] 18 [7] 15 [5] 15 [5] 
 Median [IQR] 14 [12-20] 14 [11-18] 16 [13-23] 15 [12-16] 14 [12-23] 
 Poverty (%)           <.0001a 
Mean [SD] 15 [5] 15 [5] 16[5] 18 [5] 13 [4] 
 Median [IQR] 14[12-20] 14 [12-18] 16 [13-18] 18 [13-23] 13 [10 - 14] 
 Income (%)           <.0001a 
Mean [SD] 61885 [14989] 59674 [14246] 62087 [14426] 55815 [13994] 71822 [13537] 
 Median [IQR] 59720 [53380- 57650 [49058- 56530 [54090- 55100 [41180 - 72760 [60450 -
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72760] 67180] 72110] 6390] 78760] 
Residence (%)           <.0001b 
Rural  469 (7) 370 48 35 16 
 Urban 6601 (93) 3031 1397 894 1279 
 Lesion number (%)           .091b 
Single 6822 (97) 3264 1407 900 1251 
 Multiple 248 (4) 137 38 29 44 
 Grade (%)           <.0001b 
Well differentiated 1017 (14) 532 188 135 162 
 Moderately 
differentiated 
1284 (18) 625 222 176 261 
 Poorly differentiated 503 (7) 223 85 62 133 
 Undifferentiated 45 (1) 18 4 4 19 
 Unknown 4221 (60) 2003 946 552 720 
 Stage (%)           .013b 
Localized 4066 (58) 1947 822 511 786 
 Regional 2163 (31) 1059 442 279 383 
 Distant 715 (10) 327 158 122 108 
 Unstaged 126 (2) 68 23 17 18 
 Tumor size (cm),%           <.0001b 
<3 2123 (30) 1091 421 255 356 
 3-5 2034 (29) 965 424 262 383 
 >5 2159 (31) 955 450 303 451 
 Unknown 754 (11) 390 150 109 105 
 Lymph node           .010b 
Racial disparity in overall survival in patients with hepatocellular carcinoma  
 
involvement (%) 
No lymph node 6822 (88) 2955 1270 809 1168 
 Lymph node 390 (6) 215 69 58 48 
 Unknown 478 (7) 231 106 62 79 
 Vascular Invasion (%)           .235b 
No Vascular 
Invasion 
3945 (56) 1914 802 506 723 
 Vascular Invasion 2948 (42) 1392 612 394 550 
 Unknown 177 (3) 95 31 29 22 
 Metastatic status (%)           .002b 
No metastasis 6122 (86) 2941 1238 787 1146 
 Metastasis 708 (10) 326 158 120 104 
 Unknown 250 (4) 134 49 22 45 
 AFPc (%)           <.0001b 
Positive 4552 (64) 2061 968 678 845 
 Negative 1545 (22) 821 289 137 298 
 Borderline 17 (0.2) 10 2 2 3 
 Unknown 956 (14) 509 186 112 149 
 Fibrosis (%)           <.0001b 
None to moderate 
fibrosis 
1622 (23) 723 236 220 443 
 Severe fibrosis or 
cirrhosis 
5448 (77) 2678 1209 709 852 
 Therapy (%)           <.0001b 
None 4590 (65) 2172 1052 651 715 
 Tumor destruction 787 (11) 391 141 96 159 
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Surgical resection 889 (13) 374 89 117 309 
 Liver transplantation  773 (11) 443 159 61 110 
 Unknown 31 (0.4) 21 4 4 2  
 a one-way ANOVA test 
   b Pearson Chi-Square  
  c AFP positive indicates  
AFP >15 g/ml.  
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Abstract  
Several studies have reported that metformin can reduce the risk of hepatocellular 
carcinoma (HCC) in diabetes patients. However, the direct anti-HCC effects of 
metformin have hardly been studied in patients, but have been extensively 
investigated in animal models of HCC. We therefore performed a systematic review 
and meta-analysis of animal studies evaluating the effects of metformin on HCC.  
We collected the relevant studies by searching EMBASE, Medline (OvidSP), Web of 
Science, Scopus, PubMed Publisher, and Google Scholar. Studies were included 
according to the following inclusion criteria: HCC, animal study, and metformin 
intervention. Study quality was assessed using SYRCLE’s risk of bias tool. A meta-
analysis was performed for the outcome measures: tumor growth (tumor volume, 
weight and size), tumor number and incidence. The search resulted in 573 
references, of which 13 could be included in the review and 12 included in the meta-
analysis. The study characteristics of the included studies varied considerably. Two 
studies used rats, while the others used mice. Only one study used female animals, 
nine used male, and three studies didn’t mention the gender of animals in their 
experiments.  The quality  of the included studies was low to moderate based on the 
assessment of their risk of bias. The meta-analysis showed that metformin 
significantly inhibited the growth of HCC tumour (SMD -2.20[-2.96,-1.43]; n=16), but 
no significant effect on the number of tumors (SMD-1.05[-2.13,0.03]; n=5) or the 
incidence of HCC was observed (RR 0.62[0.33,1.16]; n=6). To investigate the 
potential sources of significant heterogeneities found in outcome of tumor growth 
(I2=81%), subgroup analyses of scales of growth measures and of types of animal 
models used were performed. Metformin appears to have a direct anti-HCC effect in 
animal models. Although the intrinsic limitations of animal studies, this systematic 
review could provide an important reference for future preclinical animal trials of 
good quality and clinical development.  
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Introduction 
Hepatocellular carcinoma (HCC) is the fifth most prevalent cancer worldwide and the 
third leading cause of death from cancer. Surgical resection and liver transplantation 
are the only potentially curative treatment for a small proportion of the patients. 
However, disease recurrence hampers the ultimate success of the treatment [1]. 
Sorafenib, an oral multikinase inhibitor, was approved to treat advanced HCC. This 
however only increases patient survival with approximately 2-3 months 
[2,3].Therefore, it is necessary to explore new strategies to improve the management 
of HCC. 
Metformin is an oral drug widely used for treatment of type II diabetes. 
Interestingly, several studies, including observational studies and some randomized 
controlled trials (RCT), have reported that metformin can affect the risk of 
hepatocellular carcinoma (HCC) in diabetic patients [4-6]. Although these studies 
have suggested a preventive effect of metformin on the risk of HCC in these diabetic 
patients, there is still lacking of investigation whether metformin has direct anti-tumor 
effect in HCC patients. Nevertheless, substantial research has been performed in 
animal models of HCC, although the data are still inconclusive. Meta-analyses on 
data from animal studies can be used to explain clinical observation and to inform 
clinical trial design. 
 To better understand the direct effects of metformin on HCC and to pave the 
way for further prospective clinical study, we performed a systematic review and 
meta-analysis of currently available data from HCC animal models treated with 
metformin. 
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Results 
Description of the included studies 
The comprehensive search strategy on the effects of metformin on HCC in animal 
models resulted in 573 records. After duplicates were removed, 340 studies were 
left. After title and abstract screening, 21 studies were screened full text. Ultimately, 
13 studies were included in our systematic review [9-21], of which 12 studies (total 
29 animal experiments and 311 animals involved) could be included in the meta-
analysis (Figure 1) [9-20].  
The characteristics of all included studies are described in Table 1. Since the 
investigation of metformin on HCC using animal models has only been started in 
recent years, the publication dates of the included studies ranged from 2012 to 2014. 
Apart from these, the characteristics among these studies varied considerably. The 
characteristics of animals themselves differed substantially between the studies. 
Seven of the studies used BALB/c nude mice, and others used C57BL/6J mice, 
NOD/SCID mice, HBxTg mice, and Wistar rat. Among these studies, seven used a 
subcutaneous xenograft model, while others used oncogenic compound inducing 
models. Only half of the studies used the same dosage of metformin (250 mg/kg). 
Administration timing and duration of metformin varied greatly. Besides, various 
time-points for outcome measurements were mentioned in the studies. 
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Figure 1 Flow diagram showing literature search and selection results 
 
Risk of bias and quality of included studies  
Figure 2 shows the results of the risk of bias assessment of the 13 studies included 
in this systematic review. Based on this assessment, 7 (54%) of the studies stated 
that the allocation was randomized. Since the background of animals were 
essentially homogenous, most of the studies didn’t describe the method of 
randomization. Besides, none of the studies mentioned whether the allocation was 
adequately concealed. As shown clearly in Fig. 2, many items were scored as 
“unclear”, which indicates that reporting – and presumably experimental design - of 
these animal studies can be improved. 
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Table 1 Characteristics of the included animal studies 
Study Langu
age 
strain/Sp
ecies 
Experiment
al group 
control 
group 
Gend
er 
Age Weight animal 
number:    
c/exp 
Type of 
animal 
model  
HCC 
Numb
er/ 
anima
l  
Dosage Timing of 
metformin 
Duration of 
metformin  
Adminstration 
Route  
Outcome 
measures 
Chen           
2013[9] 
Englis
h 
BALB/c 
nude 
mice  
HCC+MET HCC F 5-6 week  * 5/5. subcutaneo
us 
xenograft  
1/1 200 mg/ml 
in drinking 
water 
10 days 
after 
implanation  
30 days orally TW 
Qu              
2012[10]  
Englis
h 
BALB/c 
nude 
mice 
HCC+MET HCC+salin
e 
M 3-4 week  14.0-
16.0 g 
12/12 ; 
12/12 
orthotopic 
xenograft  
1/1 125& 250 
mg/kg /day 
10 days 
after 
implanation 
30 days i.p. TV 
Miyoshi           
2014[11]  
Englis
h 
BALB/c-
nu/nu 
mice 
HCC+MET HCC+PBS M 8 weeks 20-25 g 10/10; 
10/10  
subcutaeno
us 
xenograft  
1/1 1& 2 
mg/body/da
y 
after an 
identifiable 
mass > 6 
mm  
14 days i.p. TV; cell cycle 
regulators;   
angiogenesis  
Bhalla     
2012[12]  
Englis
h 
C57BL/6
J mice 
HCC+MET HCC M 2 week  * 7/7. DEN  1/1 250mg/kg/d
ay  
 2 weeks 
after DEN        
168 days;  
252 days 
orally TS, TN;  
AMPK 
activation 
Kim             
2013[13]  
Englis
h 
HBxTg 
mice 
HCC+MET HBx Tg 
mice  
M * * 20/26 HBx 
Transgenic  
1/1 250mg/kg/d
ay  
6 weeks of 
age 
462 days                                    orally TN; Hepatic 
CRBP-1 
protein level, 
Akt  
DePeralt
a  
2013**[1
4]                                  
Englis
h 
Rat 
(Wistar) 
HCC+MET DEN 
induction 
M 0 week  * 9/9. DEN  1/1 250 
mg/kg/day 
8 weeks of 
age; 12 
weeks of 
age 
70 days; 42 
days 
orally TI 
Cai                 
2013[15]                          
Englis
h 
BALB/c-
nu mice 
HCC+MET HCC+PBS M 6-8 week  * 10/10. subcutaeno
us 
xenograft  
4/1 250 
mg/kg/day 
1 week 
after 
transplantat
ion 
49 days i.p. TV; cell cycle 
regulators;  p-
AMPK  
Saito        
2013[16]                            
Englis
h 
NOD/SC
ID mice 
HCC+MET HCC * * * 5/5. subcutaeno
us 
xenograft  
1/1 250 
mg/kg/day 
just after 
the 
transplantat
ion 
56 days i.p. TV; ki-67, 
casp3.  
Afzal       
2012[21]                      
Englis
h 
Wistar 
albino 
rat 
MET+DEN
A; 
DENA+ME
T 
DENA 
induction 
M Adult 100-
125g 
6/6. DENA  1/1 125mg/kg/d
ay 
 Day 1; Day 
7.  
 * i.p. animal weight,  
SGPT/ALT, 
SGOT/AST 
Tajima      
2013[17]                           
Englis
h 
C57B1/6 
mice 
non-
NAFLD+M
HFD-HFD M 8 week  * 6/4; 
17/16;4/7;4/
HFD  1/1 250 
mg/kg/day 
30 weeks 
after HFD 
210 days orally TS, TN; 
AMPK/mTOR/
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ET; 
NAFLD+M
ET 
8 S6k  
Cheng           
2014[18]                          
Englis
h 
BALB/c-
nu mice 
HCC+MET HCC M 5 week  * 28/10# subcutaeno
us 
xenograft  
4/1 30 Ag/g 
body 
weight 
1 week 
after 
transplantat
ion 
49 days i.p. TW, TI; 
activity of 
AMPK; Ki-67  
Zheng           
2013[19]                        
Englis
h 
BALB/C 
nude 
mice 
HCC+MET HCC+vehic
le 
* * * 8/8; 8/8. subcutaeno
us 
xenograft§ 
1/1 * * 49-56 days * TV; AMPK 
activation 
Xiong             
2012[20]                        
Englis
h 
BALB/c 
nude 
mice 
HCC+MET HCC+PBS * * size of 
~100mm
3 
5/5. subcutaeno
us 
xenograft  
1/1 40 & 
200mg/kg/d
ay 
7 days after 
transplantat
ion  
126 days * TV, TW 
*=not mentioned; **=only abstract available;  #= indicate tumor number; § = include two different xenograft model (HCC-LM3 and SMMC7721); MET=metformin; DEN= diethylnitrosamine (liver-specific carcinogen); FBS=fasting blood glucose; HFD= high-fat diet; 
TV=tumor volume; TW=tumor weight; TS=tumor size; TI=tumor incidence; TN=tumor number. 
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Figure 2 Risk of bias, score (%) per risk of bias item. Yes=low risk of bias, no=high risk bias, 
?=unclear risk of bias 
 
Overall analysis of the effects of metformin on HCC growth   
Ten out of the twelve studies reported outcomes related to tumor growth (tumor 
volume, tumor size or tumor weight). These 10 studies contained 18 independent 
experiments [9-12,15-20]. Of these 18 experiments, 12 showed a significant 
decrease of tumor growth. None of the experiments showed a significant increase of 
tumor growth. Meta-analysis of these experiments revealed that metformin 
intervention had a significant inhibiting effect on HCC growth (SMD -2.20[-2.96, -
1.43]; n=18) (Figure 3A). However, heterogeneity was quite high (I2 = 81%). 
 
Subgroup analysis 
To determine whether the effects differed per scale of measurement, the clinically 
relevant outcome measures including “tumor volume”, “tumor weight” and “tumor 
size” were analyzed separately in subgroups. As displayed in Figure 3B, even 
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though all three subgroups showed a statistically significant inhibition of growth, the 
effect on volume (SMD -3.11[-4.36, -1.87]; n = 10) seemed to be larger than on size 
(SMD -0.69[-1.18, -0.20]; n = 4). Besides, heterogeneity levels significantly 
decreased in the subgroup analysis of “tumor size”(I2 = 0.0%) while still high 
heterogeneity level were observed in subgroups of “tumor volume” (I2 = 82%) and 
“tumor weight” (I2 = 84%).    
In addition, a subgroup analysis was performed for the types of HCC model 
used. This analysis demonstrated that metformin had significant effect on both 
xenograft (SMD -2.77[-3.74, -1.79]; n = 14) and non-xenograft model (SMD -0.69[-
1.18, -0.20]; n=4), but the former group seemed to be affected by metformin more 
than the latter group. Subgroup analysis of “non-xenograft model” clearly reduced 
heterogeneity (I2=0.0%), while “xenograft model” subgroup analysis did not  change 
high heterogeneity level.   
 
Effects of metformin on HCC number  
In addition to the analysis of the effect on tumor growth, we also did analysis on HCC 
number in five animal experiments. Of these five experiments, four showed a 
significant decrease of HCC number and none showed a significant increase. 
Although it was unclear how the data were presented in DePeralta’s study [14], we 
assumed they were presented as mean ± SE. The result didn’t show significant 
inhibitory effect on HCC tumor number by metformin (SMD -1.05[-2.13, 0.03]; n = 5) 
(Figure 4). We found high heterogeneity (I2 = 78%). 
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Figure 3 Effects of metformin on tumor growth in HCC animal models. (A) Forest plot and (B) 
subgroup analysis of the 16 included studies. The forest plot displays the SMD, confidence interval, 
and effect weight for each study, plus the pooled effect estimate & confidence interval.  
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Figure 4  Effects of metformin on tumor number in HCC animal models.  
 
Effects of metformin on HCC incidence  
The effects of metformin on the incidence of HCC in animal models was evaluated. 
Only two studies showed a significant decrease of HCC incidence; whereas the 
others showed trend of decrease but one showed a trend of increase. However, the 
meta-analysis didn’t show a significant effect of metformin on the incidence of HCC 
in comparison with non-treatment group (RR 0.62[0.33,1.16]; n=6) (Figure 5). The 
heterogeneity was high (I2 = 83%). 
 
 
Figure 5  Effects of metformin on tumor incidence in HCC animal models  
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Sensitivity analysis  
We performed sensitivity analysis to assess the robustness of our results on the 
effects of metformin on HCC number. In the subgroup analysis of “tumor number”, 
we assumed that DePeralta [14]presented the data as mean ± SE. For this 
sensitivity analysis we test the assumption that the data were presented as mean ±  
SD. With this assumption the meta-analysis showed that metformin could 
significantly reduce HCC tumor number (SMD -1.21[-2.29, -0.13];n=5). This result 
differs from our previous findings in the subgroup analysis. Interpretation of this 
outcome measure should be done with extreme caution, as current available 
evidence is still inconclusive. 
 
Publication bias 
Publication bias was assessed for the outcome of overall tumor growth, since the 
analysis of this outcome included the highest number of studies. On visual inspection 
of the funnel plot (Figure 6), small studies with no or a negative effect seem to be 
missing. This asymmetry might indicate the presence of publication bias.  
 
 
 
Figure 6  Funnel plot overseeing publication bias of included studies 
Chapter 6 
 
 135 
Discussion 
Although there were already several clinical studies evaluating the effects of 
metformin on HCC risk in human population, all of them were on the chemo-
preventive effect by metformin rather than the therapeutic effect and, moreover, the 
population were all diabetic patients. A meta-analysis of the effects of anti-diabetic 
medications on the HCC risk, in which both observational and RCT studies were 
included, has suggested a half reduction in HCC incidence when using metformin 
treatment [22]. However, our meta-analysis systematically analyzed all relevant 
animal studies to assess the therapeutic potential of metformin against HCC. 
In this comprehensive systematic review and meta-analysis, we analyzed and 
described the effects of metformin on HCC growth and incidence. The overall 
analysis of the effect of growth showed that use of metformin was associated with a 
significant inhibitory effect (SMD= -2.20 ± 0.76) on HCC growth, compared to 
untreated group. This therapeutic effect remained stable across subgroups of tumor 
volume, tumor weight and tumor size. It was most pronounced in “tumor volume” 
measurement while least in “tumor size” measurement. Besides, we performed 
subgroup analysis under the “tumor growth”. Both xenograft and non-xenograft 
studies showed significant inhibitory effect of metformin on HCC growth.  
 
Mechanism underlying metformin anti-HCC 
The anti-cancer effect of metformin was speculated to be associated with the 
activation of adenosine monophosphate-activated protein kinase (AMPK). An 
important upstream kinase of AMPK is LKB1, an very important tumor suppressor 
[23,24]. This signaling pathway was also discussed and explored in the included 
HCC animal trials. The coexistence of AMPK-dependent and AMPK-independent 
mechanisms for the effects of metformin on cancer was proposed[9,10,12,15]. But 
we should keep in mind of different study methodologies. For instance, two studies 
used cell lines in vitro[9,15]; one study used tumor harvested from xenograft[10]; 
whereas one study demonstrated their result based on observing AMPK level in 
liver[12]. In addition, metformin may also inhibit HCC cell growth by regulating cell-
cycle regulatory proteins, such as cyclin D1 and cyclin E [10,14]. Of particular note, 
c-myc was suggested as a critical mediator in hepatocarcinogenesis [25]. Metformin 
treatment has been shown to inhibit c-myc expression by up-regulating let-7 family 
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(tumor suppressor) [11]. However, no study among the included animal studies 
discussed such mechanism underlying specific HCC stage. Although we found one 
human study relevant to early stage of HCC, no clear mechanistic insight of 
metformin on early stage HCC was described[26]. 
 
Side effects of metformin in animal models 
Being a classic antidiabetic medication, metformin is widely used among patients 
because of its relatively low cost and high safety profile. 10 out of 13 studies 
included in this systematic review mentioned tolerability of metformin treatment. 
These studies consistently showed that metformin didn’t change body weight and 
serum glucose level of animals. However, it should also be taken into consideration 
of further investigation on the appropriate therapeutic dosage rang of metformin for 
anti-cancer treatment. Evaluation of safety with these particular dosages is very 
necessary, especially when metformin is applied in non-diabetic patients. 
 
Limitations  
By using the risk of bias tool, we found out that reporting is poor and therefore the 
methodological quality of many studies is unclear. It shows that there is much room 
for improvement, since many items were shown “unclear” and only a few items were 
shown low risk only in very few studies. Besides, by visualizing the funnel plot, 
publication bias seems also to be present, probably due to the missing of studies 
with no or negative effects. Actually, in total, only 12 studies were included in the 
meta-analysis. Both the unclear methodological quality and publication bias  might 
lead to under or overestimation of the overall effect size of metformin effect on anti-
HCC, which is an additional threat to the robustness of the data especially the ones 
that are already inconclusive. What’s more,  high heterogeneity was also seen 
among the studies, which is common in animal studies, although we tried to explore 
the potential factors contributing the heterogeneity. All of these potential limitations 
might influence us to draw concrete conclusions on the anti-HCC effect of metformin.  
Besides, there were some methodological issues which might influence the 
translation of animal results to human trials. Firstly, the literature is unclear about 
which animal method is most representative for patient HCC. We found various HCC 
methods used in these studies: xenograft, DEN-induction, transgenic and dietary 
models. Secondly, there are two different administration routes (oral or i.p.) of 
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metformin in the studies. However, metformin is usually an orally administrated drug 
in clinic, raising the question whether administration method could also affect the 
effect of metformin on tumor.  
          HCC invasion and metastasis are crucial factors related to poor prognosis. 
However, none of the animal studies described if metformin had potential effect on 
HCC metastasis, except one study indirectly mentioned correlation of metformin/p-
AMPK with distant metastasis in human HCC cohort study [19]. 
         Another limitation is that these animal studies did not study the HCC stage 
indicated for metformin. HCC stage could be an important factor for the therapeutic 
efficacy of metformin and has implication for selecting appropriate candidates for 
metformin treatment. Therefore, it’s very necessary to take the stage of HCC into 
account in the experimental design. As for xenograft animal model, which were used 
in most of the studies, however, it’s hard to define the cancer stage which didn’t 
discuss in the studies. In addition, although it’s possible to identify tumor stage in 
spontaneous animal tumor model, the authors did not report any information about 
HCC stage in their animal study[12,17].   
 
Implications for practice  
Based on the results of this meta-analysis, metformin could potentially have a 
therapeutic effect on HCC. Besides, the maximal dose of metformin used in all the 
included animal studies were consistent with human therapeutic dose in diabetics 
according to the calculation [10]. This furthermore supported the reliable and 
applicable results from animal models. Although several clinical studies reported that 
metformin could negatively modify the risk of HCC in diabetic patients [4-6], there are 
not yet any clinical trial investigating the therapeutic effect of metformin on HCC. 
Currently, several ongoing clinical trials (www.clinicaltrials.gov) are evaluating the 
effects of metformin on different cancers (breast cancer, colorectal cancer, 
pancreatic cancer, etc.), But not for HCC. Thus, the results of this systematic review 
provide an important reference for the future preclinical animal trials with high quality 
to aid the development of metformin for anti-HCC treatment in clinical trials. 
Considering the dominant risk factor for HCC in many western countries in particular 
United States--obesity and metabolic syndrome, metformin would be an appropriate 
choice for such a high-risk of population of HCC. 
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CONCLUSION 
In summary, this systematic review of animal studies suggests that metformin 
potentially has a direct inhibitory effect on HCC growth, although the effects on tumor 
number and incidence are inconclusive. It supports the clinical observation that 
metformin is associated with lower risk of HCC in diabetic patients. Although these 
animal studies have some intrinsic limitations, these results do provide an important 
reference for future high-quality preclinical animal trials and potential clinical 
development.  
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Methods 
 
Review protocol 
A protocol for this systematic review was prepared using SYRCLE’s protocol format 
(https://www.radboudumc.nl/Research/Organisationofresearch/Departments/cdl/SYR
CLE/Pages/Protocols.aspx )[7]. 
 
 Literature search 
A systematic search (conducted on July 2014, without any restrictions on publication 
data or language) was conducted in Medline (OvidSP),  Embase.com, Web of 
Science, and Scopus. Additional referenes were retrieved from Google Scholar, and 
unindexed references from PubMed. The searches were designed and executed by 
an experience information specialist (WB). The search strategy consisted of two 
main components: hepatocellular carcinoma, and metformin, and results were limited 
to animal studies.  For each element multiple synonyms were searched in title and/or 
abstract, and when available thesaurus terms (Mesh for medline and Emtree for 
embase). The full strategy is available in supplementary S1 Table. 
 
Study selection and inclusion criteria 
The selection procedure was performed by two independent reviewers (J.L. and 
P.H.). The exclusion criteria for the title and abstract screening phase include: 1). not 
primary study; 2). not animal study; 3). not disease of interest (HCC), 4). not 
intervention of interest (metformin). The following additional criteria were used for 
full-text screening: 1). full-text not available; 2). double publication; 3). conference 
abstracts. In case of disagreement between the reviewers, consensus was reached. 
 
Study characteristics and data extraction 
Data was extracted from the full-text papers of the studies. The following items were 
extracted: author, year, language, species/strain, description of control group, animal 
gender, age and weight, number of animals in control and experimental group, the 
method for the establishment of the animal models, metformin dosage, timing, 
duration and route of metformin administration, and outcome measures (Table 1). 
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The outcome measures including HCC growth, number and incidence were 
included in the meta-analysis. Mean value, standard deviation (SD) and the number 
of animals per group were extracted. If relevant data were not available in the text 
but only presented in graphic form, obtaining the data by measuring the graphs using 
Universal Desktop Ruler (Universal On-screen Digitizer, AVPSoft.). 
 
Quality assessment of included studies 
The SYRCLE’s Risk of Bias tool was used to assess the risk of bias of all included 
studies [8]. Two independent investigators (J.L.&P.H.) performed quality assessment 
of all included studies. Disagreements were resolved by discussion.  
 
Data synthesis and statistical analysis 
For the outcome measures of HCC growth and number, the standardized mean 
difference (SMD) was used as the effect measure. For the outcome measure of HCC 
incidence, Risk Ratio (RR) was used. If studies contained multiple independent 
groups (e.g. different animal models or different time points), they were treated as 
separate experiments. Because of expected heterogeneity, the statistical model of 
analysis used in this meta-analysis was a random effects model. I2 was used as a 
measure of heterogeneity. In order to explore potential causes of heterogeneity, 
predefined subgroup analyses were conducted for tumor volume, weight and size. 
With assistance of RevMan5.3 (Cochrane Library) software, Forest Plots were 
established. In addition, sensitivity analyses were conducted as to evaluate whether 
the findings were robust enough to the decisions made. Visual inspection of funnel 
plots was used to detect publication bias. Our procedures accorded with PRISMA 
guidelines for reporting systematic review/meta-analysis(supplementary S2 Table). 
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Supplementary Data 
 
Table S1  Search Strategy 
embase.com    133 
Component 1: 
hepatocellular 
carcinoma 
('liver cell carcinoma'/de OR 'hepatocellular carcinoma cell line'/exp OR 
'hepatoma cell'/de OR (((liver OR hepat*) NEAR/6 (carcino* )) OR hepatoma* 
OR (hepatocell* NEAR/3 cancer*) OR hepatocarcinom* OR hepatoma OR 
'AH 109a' OR AH109a OR 'AH 130' OR AH130 OR 'AH 272' OR AH272 OR 
'AH 66' OR AH66 OR HepG2 OR 'Hep G2' OR hcc):ab,ti) 
Component 2: 
metformin 
AND (metformin/de OR (metformin* OR metphormin* OR methformin* OR 
metaformin* OR dimethylbiguanide OR 'dimethyl biguanide' OR 
dimethyldiguanide OR dimethylguanylguanidine OR apophage OR aron OR 
benofomin OR dabex OR denkaform OR deson OR dextin OR diabetase OR 
diabetformin OR diabetmin OR diabetosan OR diabex OR diafat OR diaformin 
OR diaformina OR diametin OR diamin OR diformin OR dimefor OR 
dimethylbiguanide OR dimethyldiguanide OR dmgg OR dybis OR eraphage 
OR espa-formin OR 'euform retard' OR fluamine OR flumamine OR fornidd 
OR fortamet OR glafornil OR glibudon OR glifage OR gliguanid OR 
glucaminol OR glucofage OR glucofago OR glucoform OR glucoformin OR 
glucohexal OR glucoless OR glucomet OR glucomin OR glucomine OR 
gluconil OR glucophage OR glucotika OR gludepatic OR glufor OR gluformin 
OR glumeformin OR glumet OR glumetza OR glupa OR glustress OR 
glyciphage OR glycomet OR glycon OR glycoran OR glyformin OR glymet OR 
haurymellin OR hipoglucin OR i-max OR islotin OR juformin OR 'la 6023' OR 
la6023 OR maformin OR meglucon OR meguan OR melbin OR melformin OR 
mellittin OR mescorit OR metaformin OR metfogamma OR metforal OR 
metformin* OR methformin OR metiguanide OR metomin OR metphormin OR 
miformin OR neoform OR nndg OR reglus-500 OR riomet OR siamformet OR 
siofor OR thiabet OR vimetrol OR walaphage):ab,ti) 
Component 3: 
animal 
NOT ([humans]/lim NOT [animals]/lim) 
Medline (OvidSP)  82 
Component 1: 
hepatocellular 
carcinoma 
("Carcinoma, Hepatocellular"/ OR (((liver OR hepat*) ADJ6 (carcino* )) OR 
hepatoma* OR (hepatocell* ADJ3 cancer*) OR hepatocarcinom* OR "AH 
109a" OR AH109a OR "AH 130" OR AH130 OR "AH 272" OR AH272 OR "AH 
66" OR AH66 OR HepG2 OR "Hep G2" OR hcc).ab,ti.) 
Component 2: 
metformin 
AND (metformin/ OR (metformin* OR metphormin* OR methformin* OR 
metaformin* OR dimethylbiguanide OR "dimethyl biguanide" OR 
dimethyldiguanide OR dimethylguanylguanidine OR apophage OR aron OR 
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benofomin OR dabex OR denkaform OR deson OR dextin OR diabetase OR 
diabetformin OR diabetmin OR diabetosan OR diabex OR diafat OR diaformin 
OR diaformina OR diametin OR diamin OR diformin OR dimefor OR 
dimethylbiguanide OR dimethyldiguanide OR dmgg OR dybis OR eraphage 
OR espa-formin OR "euform retard" OR fluamine OR flumamine OR fornidd 
OR fortamet OR glafornil OR glibudon OR glifage OR gliguanid OR 
glucaminol OR glucofage OR glucofago OR glucoform OR glucoformin OR 
glucohexal OR glucoless OR glucomet OR glucomin OR glucomine OR 
gluconil OR glucophage OR glucotika OR gludepatic OR glufor OR gluformin 
OR glumeformin OR glumet OR glumetza OR glupa OR glustress OR 
glyciphage OR glycomet OR glycon OR glycoran OR glyformin OR glymet OR 
haurymellin OR hipoglucin OR i-max OR islotin OR juformin OR "la 6023" OR 
la6023 OR maformin OR meglucon OR meguan OR melbin OR melformin OR 
mellittin OR mescorit OR metaformin OR metfogamma OR metforal OR 
metformin* OR methformin OR metiguanide OR metomin OR metphormin OR 
miformin OR neoform OR nndg OR reglus-500 OR riomet OR siamformet OR 
siofor OR thiabet OR vimetrol OR walaphage).ab,ti.) 
Component 3: 
animal 
NOT (humans/ NOT animals/) 
Web-of-science  100 
Component 1: 
hepatocellular 
carcinoma 
TS=(((((liver OR hepat*) NEAR/6 (carcino* )) OR hepatoma* OR (hepatocell* 
NEAR/3 cancer*) OR hepatocarcinom* OR hepatoma OR "AH 109a" OR 
AH109a OR "AH 130" OR AH130 OR "AH 272" OR AH272 OR "AH 66" OR 
AH66 OR HepG2 OR "Hep G2" OR hcc)) 
Component 2: 
metformin 
AND ((metformin* OR metphormin* OR methformin* OR metaformin* OR 
dimethylbiguanide OR "dimethyl biguanide" OR dimethyldiguanide OR 
dimethylguanylguanidine OR apophage OR aron OR benofomin OR dabex 
OR denkaform OR deson OR dextin OR diabetase OR diabetformin OR 
diabetmin OR diabetosan OR diabex OR diafat OR diaformin OR diaformina 
OR diametin OR diamin OR diformin OR dimefor OR dimethylbiguanide OR 
dimethyldiguanide OR dmgg OR dybis OR eraphage OR espa-formin OR 
"euform retard" OR fluamine OR flumamine OR fornidd OR fortamet OR 
glafornil OR glibudon OR glifage OR gliguanid OR glucaminol OR glucofage 
OR glucofago OR glucoform OR glucoformin OR glucohexal OR glucoless OR 
glucomet OR glucomin OR glucomine OR gluconil OR glucophage OR 
glucotika OR gludepatic OR glufor OR gluformin OR glumeformin OR glumet 
OR glumetza OR glupa OR glustress OR glyciphage OR glycomet OR glycon 
OR glycoran OR glyformin OR glymet OR haurymellin OR hipoglucin OR i-
max OR islotin OR juformin OR "la 6023" OR la6023 OR maformin OR 
meglucon OR meguan OR melbin OR melformin OR mellittin OR mescorit OR 
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metaformin OR metfogamma OR metforal OR metformin* OR methformin OR 
metiguanide OR metomin OR metphormin OR miformin OR neoform OR nndg 
OR reglus-500 OR riomet OR siamformet OR siofor OR thiabet OR vimetrol 
OR walaphage)) 
Component 3: 
animal 
AND (mice OR mouse OR rat OR rats))  
Scopus   106 
Component 1: 
hepatocellular 
carcinoma 
TITLE-ABS-KEY(((((liver OR hepat*) W/6 (carcino* )) OR hepatoma* OR 
(hepatocell* W/3 cancer*) OR hepatocarcinom* OR hepatoma OR "AH 109a" 
OR AH109a OR "AH 130" OR AH130 OR "AH 272" OR AH272 OR "AH 66" 
OR AH66 OR HepG2 OR "Hep G2" OR hcc)) 
Component 2: 
metformin 
AND ((metformin* OR metphormin* OR methformin* OR metaformin* OR 
dimethylbiguanide OR "dimethyl biguanide" OR dimethyldiguanide OR 
dimethylguanylguanidine OR apophage OR aron OR benofomin OR dabex 
OR denkaform OR deson OR dextin OR diabetase OR diabetformin OR 
diabetmin OR diabetosan OR diabex OR diafat OR diaformin OR diaformina 
OR diametin OR diamin OR diformin OR dimefor OR dimethylbiguanide OR 
dimethyldiguanide OR dmgg OR dybis OR eraphage OR espa-formin OR 
"euform retard" OR fluamine OR flumamine OR fornidd OR fortamet OR 
glafornil OR glibudon OR glifage OR gliguanid OR glucaminol OR glucofage 
OR glucofago OR glucoform OR glucoformin OR glucohexal OR glucoless OR 
glucomet OR glucomin OR glucomine OR gluconil OR glucophage OR 
glucotika OR gludepatic OR glufor OR gluformin OR glumeformin OR glumet 
OR glumetza OR glupa OR glustress OR glyciphage OR glycomet OR glycon 
OR glycoran OR glyformin OR glymet OR haurymellin OR hipoglucin OR i-
max OR islotin OR juformin OR "la 6023" OR la6023 OR maformin OR 
meglucon OR meguan OR melbin OR melformin OR mellittin OR mescorit OR 
metaformin OR metfogamma OR metforal OR metformin* OR methformin OR 
metiguanide OR metomin OR metphormin OR miformin OR neoform OR nndg 
OR reglus-500 OR riomet OR siamformet OR siofor OR thiabet OR vimetrol 
OR walaphage)) 
Component 3: 
animal 
AND (mice OR mouse OR rat OR rats OR animal*))  
PubMed Publisher  2 
Component 1: 
hepatocellular 
carcinoma 
((((liver OR hepat*[tiab]) AND (carcino*[tiab] )) OR hepatoma*[tiab] OR 
(hepatocell*[tiab] AND cancer*[tiab]) OR hepatocarcinom*[tiab] OR AH 109a 
OR AH109a OR AH 130 OR AH130 OR AH 272 OR AH272 OR AH 66 OR 
AH66 OR HepG2 OR Hep G2 OR hcc)) 
Component 2: 
metformin 
AND ((metformin*[tiab] OR metphormin*[tiab] OR methformin*[tiab] OR 
metaformin*[tiab] OR dimethylbiguanide OR dimethyl biguanide OR 
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dimethyldiguanide OR dimethylguanylguanidine OR apophage OR aron OR 
benofomin OR dabex OR denkaform OR deson OR dextin OR diabetase OR 
diabetformin OR diabetmin OR diabetosan OR diabex OR diafat OR diaformin 
OR diaformina OR diametin OR diamin OR diformin OR dimefor OR 
dimethylbiguanide OR dimethyldiguanide OR dmgg OR dybis OR eraphage 
OR espa-formin OR euform retard OR fluamine OR flumamine OR fornidd OR 
fortamet OR glafornil OR glibudon OR glifage OR gliguanid OR glucaminol 
OR glucofage OR glucofago OR glucoform OR glucoformin OR glucohexal 
OR glucoless OR glucomet OR glucomin OR glucomine OR gluconil OR 
glucophage OR glucotika OR gludepatic OR glufor OR gluformin OR 
glumeformin OR glumet OR glumetza OR glupa OR glustress OR glyciphage 
OR glycomet OR glycon OR glycoran OR glyformin OR glymet OR 
haurymellin OR hipoglucin OR i-max OR islotin OR juformin OR la 6023 OR 
la6023 OR maformin OR meglucon OR meguan OR melbin OR melformin OR 
mellittin OR mescorit OR metaformin OR metfogamma OR metforal OR 
metformin*[tiab] OR methformin OR metiguanide OR metomin OR 
metphormin OR miformin OR neoform OR nndg OR reglus-500 OR riomet OR 
siamformet OR siofor OR thiabet OR vimetrol OR walaphage)) 
Component 3: 
animal 
AND (mice OR mouse OR rat OR rats OR animal*) AND publisher[sb] 
Google Scholar 150 
Component 1: 
hepatocellular 
carcinoma 
"liver cell carcinoma"|"hepatocellular 
carcinoma|cancer"|hepatoma|hepatocarcinoma 
Component 2: 
metformin 
Metformin 
Component 3: 
animal 
mice|mouse|rat|rats|animal|animals 
 
 
 
 
 
 
Chapter 6 
 
 
145 
Table S2 PRISMA  Checklist for the Systematic Review and Meta-analysis to Estimate the anti-HCC effect of metformin in animal studies  
 
Section/topic 
# Checklist item  
Reporte
d on 
page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
4 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
 5 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
5 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched.  
5 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it S1 table 
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could be repeated.  
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
5 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and 
any processes for obtaining and confirming data from investigators.  
5-6 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
6 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in any 
data synthesis.  
6 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  6 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
6-7 
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
6-7 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified.  
7 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
8+fig1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-
up period) and provide the citations.  
Table1 
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Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 
12).  
Fig2 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for 
each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Fig3-5 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
9-10 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  11 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression 
[see Item 16]).  
9-11 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
12,13,
15 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
14 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for 
future research.  
16 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 
funders for the systematic review.  
17 
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Chapter 7     General discussion, summary and conclusion  
 
The liver is an organ of vital importance as it supports almost every other organ in 
the human body. Because of its strategic location with respect to the intestine and its 
plethora of functions, the liver is also prone to many diseases. Especially viral 
hepatitis is a common condition of inflammation of the liver. Among both the most 
usual causes of viral infection and also clinically potentially most serious are the 
hepatitis B and C viruses. Some of these infections are sexually transmitted or by 
dirty needles among intravenous drug users and thus co-infection with HIV is 
depressingly common.  Infection with hepatitis B virus or hepatitis C virus is the main 
cause of liver cancer. At present reliable assessment of liver condition in chronic viral 
hepatitis is problematic and relies histological assessment of invasive liver biopsies. 
This situation prompts investigation into more convenient biomarkers. This 
consideration prompted me to investigate caspase-cleaved cytokeratin 18 (CK18-
Asp396) as a serum marker for disease activity. I considered this a potential clinically 
useful biomarker in liver disease as it is released from hepatocytes during apoptosis. 
In Chapter 2, I investigate serum CK18-Asp396 levels in a well characterized Dutch 
cohort consisting of patients with chronic hepatitis B infection across all grades of 
steatosis, inflammation and fibrosis. We exploited this notion to evaluate hepatocyte 
apoptosis in CHB. The study demonstrated that CHB is indeed associated with 
hepatocyte apoptosis, showing strong correlations with significant inflammation and 
fibrosis, but not with steatosis, and especially demonstrating a diagnostic value of 
CK-18 serum levels for identification of significant inflammation of the liver in CHB 
patients with a high specificity. The availability of such a biomarker should 
substantially aid future studies in disease course modifying parameters.  
As said, chronic viral infection of the liver is often associated with HIV infection. 
Hence understanding response of therapy to anti-HIV drugs is also relevant in the 
context of the present dissertation. The factors associated of overall survival in 
patients with HIV that receive ART initiation was analyzed in Chapter 3. Consistent 
with previous studies, a male sex, increasing age, advanced WHO clinical stage 
were demonstrated to be related to worse overall survival. But interestingly, our 
result revealed the time-dependent effect of CD4 cell counts on the long-term 
outcome of patients. We found that, although the baseline CD4 cell count is 
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positively associated with overall survival in the first six months of ART initiation, it 
becomes weak after six months. These results reveal the importance of the time 
domain when analyzing this type of epidemiological data. Furthermore, coinfection 
with hepatitis virus was also analyzed for its prevalence and impact on clinical 
outcome of HIV infected patients. Our data suggest no significant relation between 
coinfection with hepatitis virus and patients' outcome. As extensively discussed in 
Chapter 4, data on coinfection affecting HIV patient survival remains under debate. 
The surprising nature of our results could be possibly related to several factors, such 
as patient population, follow up time, and adjusted confounders, etc.. I feel, however, 
that it shows the importance of performing this type of study, as it seems that we 
often take a too simplistic look at our data. This notion is also highlighted by the 
results in the remainder of my thesis, in which I look at liver cancer, a feared 
complication of chronic viral hepatitis.  
Liver cancer, known also as hepatic cancer or primary hepatic cancer, is cancer 
that starts in the liver, in contrast to cancer that has spread from elsewhere to the 
liver, which we know as liver metastasis. Symptoms of liver cancer may include a 
lump or pain in the right side below the rib cage, swelling of the abdomen, yellowish 
skin, easy bruising, weight loss, and weakness. The leading cause of liver cancer is 
cirrhosis due to hepatitis B, hepatitis C, or alcohol. Other causes include aflatoxin 
and non-alcoholic fatty liver disease. The most common types are hepatocellular 
carcinoma (HCC), which makes up 80% of cases. Following the established poor 
survival of HCC among African Americans, many studies were carried out to provide 
evidence on this survival disparity.[1-3]  Although several factors have been 
identified as contributors to such disparity including advanced tumor presentation at 
time of diagnosis, restricted access to liver transplantation, and lower SES, none of 
previous studies have analyzed the actual impact of each contributor to patients' 
survival. Therefore, based on SEER database, we aimed to identify contributors to 
the racial disparity in overall survival through a strategic modeling analysis. Our data 
suggest that tumor presentation at diagnosis, limited benefit from resection and 
restricted utilization of liver transplantation are important contributors to poorer 
survival of African Americans with hepatocellular carcinoma (Chapter 5). It would be 
interesting to investigate the same question in European cohorts. The Erasmus MC 
being an important referral center for this disease would be a good place for such 
studies. Health care is equally accessible to the whole population in the Netherlands 
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and thus it would be interesting to study the effect of socioeconomic status in the 
Dutch context. Both patient-related and physician-related factors may still influence 
treatment choices and thus results. 
Indeed, treatment is important in predicting outcome for hepatocellular 
carcinoma. In very early and early stage HCC, surgical therapy such as resection 
and liver transplantation constitute curative treatment. In advanced stage HCC, 
systematic chemotherapy with sorafenib is the only one FDA-approved first line 
treatment available.[4] However, this therapy can only increase overall median 
survival with 2-3 months.[5] Therefore, new strategies to improve the management of 
HCC are very necessary. Metformin, an oral drug widely used for treating type II 
diabetes, were reported to be associated with low risk of HCC. However, there is a 
lack of investigations assessing whether metformin has direct anti-tumor effects in 
HCC patients. Giving substantial research having been performed in animal models 
of HCC, I performed a systematic review and meta-analysis on those data from 
previous animal studies to better understand the direct effects of metformin on HCC, 
the results have been shown in Chapter 6. This study suggests that metformin can 
potentially have a direct inhibitory effect on HCC growth. Although these animal 
studies have some intrinsic limitations, our results do provide an important reference 
for future high-quality preclinical animal trials and potential clinical development. 
Moreover, considering the dominant risk factor for HCC in many western countries in 
particular United States--obesity and metabolic syndrome, metformin would be an 
appropriate choice for such a high-risk of population of HCC. 
In conjunction, I feel my studies add to the framework necessary for improved 
analysis of liver disease, for instance by identifying novel biomarkers (chapter 2), 
but also by showing the use of meta-analysis as a strategy towards understanding of 
preclinical studies of liver disease (chapter 6) or by identifying the importance of the 
time domain in analyzing epidemiological results on the natural history of disease 
(chapter 3 and chapter 5). Simultaneously, I have employed these concepts to 
obtain insight in factors in contributing or not contributing to alternative disease 
course (chapter 4 or chapter 6, for instance). Thus I hope with this work to have 
added to the efforts to come to better management of liver disease). 
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Nederlandse samenvatting voor niet ingewijden 
 
De lever is een belangrijk en veelzijdig orgaan bij de mens. Ze speelt een belangrijke 
rol in het metabolisme en vrijwel alle andere organen zijn op één of andere wijze wel 
afhankelijk van de lever. In het menselijke lichaam is de lever beveiligd door de 
onderste ribben van de borstkas, rechtsboven in de buikholte. Met een gewicht van 
anderhalve kilogram is het na de huid het zwaarste orgaan en wellicht ook het 
veelzijdigste orgaan. Ziekte aan de lever heeft dan ook ernstige consequenties voor 
de betrokken patiënten. In hoofdstuk één van dit proefschrift zet ik uiteen welke 
vragen ik denk dat beantwoord moeten worden om dit veld verder te brengen  
In dit proefschrift concentreer ik me dan in eerste instantie mij op leverontsteking of 
hepatitis Het woord hepatitis komt uit het Grieks en Latijn en bestaat uit twee delen: 
'ἡπαρ' (hèpar) en '-itis'. Hepar betekent lever en het achtervoegsel -itis betekent 
ontsteking. Hepatitis betekent dus een ontsteking van de lever. Dit kan verschillende 
oorzaken hebben, maar met name virale hepatitis kan verstrekkende gevolgen 
hebben.Er worden nog steeds nieuwe hepatitisvirussen ontdekt die een ontsteking 
van de lever kunnen geven maar in het kader van dit proefschrift zijn met name 
hepatitis B virus en hepatitis C virus belangrijk. Chronische hepatitis B kan na een 
infectie met het hepatitis B-virus ontstaan als het lichaam niet in staat is het virus te 
klaren. Een chronische infectie met het hepatitis B-virus kan zowel asymptomatisch 
zijn (in het merendeel van de gevallen) als gekoppeld zijn aan een chronische 
ontsteking van de lever (chronische hepatitis). Ook  een hepatitis C-infectie verloopt 
in het begin meestal asymptomatisch. De infectie gaat in de meerderheid van de 
gevallen (70%) ongemerkt over in een chronische vorm.De chronische ontsteking 
kan na meerdere jaren leiden tot cirrose en leverkanker. Het is belangrijk de reactie 
van lever op een virale hepatitis goed te kunnen volgen. Nu gebeurt dat vaak door 
leverbiopten te laten beoordelen onder de microscoop door de patholoog. 
Leverbiopten nemen is echter invasief, pijnlijk en niet zonder risico. Er is dus grote 
behoefte aan een betere methode. In hoofdstuk twee van dit proefschrift exploreer 
ik cytokeratine 18 fragmenten als een nieuwe methode. Cytokeratine 18 is een taai, 
onoplosbaar eiwit dat voorkomt in de lever. Als levercellen doodgaan door 
geprogrammeerde celdood, komen er echter oplosbare fragmenten in de 
bloedsomloop terecht. Omdat virale infectie gepaard gaat met geprogrammeerde 
celdood in de lever redeneerde ik dat cytokeratine 18 fragment in de bloedsomloop 
een mooie maat zouden zijn voor virale infectie van de lever. In dit proefschrift laat ik 
zien dat deze redenering klopt. 
 Intraveneus drugsgebruik en seksueel contact zijn belangrijke bronnen van 
transmissie van hepatitis virussen, maar dezelfde risicofactoren zijn ook gerelateerd 
aan HIV infectie. Er is dan ook vaak co-infectie van hepatitis virus en HIV. Gelukkig 
kan HIV vaak behandeld worden met antivirale therapie. In hoofdstuk drie laat ik 
zien dat de grootte van een populatie van witte bloedcellen, de CD4 T cellen een 
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goede voorspeller vormt van het succes van antivirale therapie, maar alleen vroeg in 
het natuurlijk verloop van de ziekte. Het is belangrijk het tijdsdomein mee te nemen 
in analyse van factoren die gerelateerd zijn aan het verloop van ziekte. Ook 
verrassend was de uitkomst van de analyse in hoofdstuk vier, hier laat ik zien dat 
co-infectie niet van invloed is op therapiesucces in patiënten geïnfecteerd met zowel 
hepatis C als HIV. Mijn resultaten laten dus zien dat interpretatie van 
epidemiologische data met grootste zorgvuldigheid dient te gebeuren. 
Gewapend met deze kennis stortte ik mij vervolgens op leverkanker. Hiermee 
bedoelt men een primaire kwaadaardige tumor die in de lever is ontstaan. Primaire 
leverkanker komt slechts zelden voor in Nederland, maar elders maken de frequente 
besmettingen met hepatitis (vooral hepatitis B), en het gebruik van voedsel dat is 
bedorven door de schimmel Aspergillus flavus, die aflatoxine produceert dit een 
groot probleem. In mijn onderzoek, beschreven in hoofdstuk vijf, maakte ik gebruik 
van een Amerikaanse database en analyseer het effect van ras op de uitkomst van 
leverkanker. Het blijkt dat vooral mensen van Afrikaanse afkomst het slecht doen en 
ik probeer de oorzaken te achterhalen. In hoofdstuk zeven speculeer ik over de 
noodzaak om een dergelijke studie ook in Nederland uit te voeren. De belangrijkste 
reden voor de relatieve overstrefte in patiënten van Afrikaanse afkomst lijkt te liggen 
in verschillen in de behandeling. Dit brengt mij op het punt van dat het noodzakelijk 
is om nieuwe behandelingen te vinden. Zulk onderzoek vindt vaak eerst plaats in 
pre-klinische modellen. Interpretatie van de resultaten van zulk pre-klinisch 
onderzoek is vaak lastig. In hoofdstuk zes laat ik een nieuwe aanpak zien hoe de 
literatuur te onderzoeken. Het succes van deze aanpak blijkt uit mijn bevinding dat 
metformine effectief uit zulke modellen. Verdere interpretatie en integratie van 
bevindingen alsmede speculatie over toekomstig onderzoek kan men vinden in 
hoofdstuk zeven. Samen hoop ik, dat ik met deze dissertatie een bijdrage heb 
kunnen leveren aan toekomstig onderzoek gericht op de betere behandeling van 
leverziekte, 
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